1
|
Menzies D, Obeng J, Hadisoemarto P, Ruslami R, Adjobimey M, Fisher D, Barss L, Bedingfield N, Long R, Paulsen C, Johnston J, Romanowski K, Cook VJ, Fox GJ, Nguyen TA, Valiquette C, Oxlade O, Fregonese F, Benedetti A. Sustainability and impact of an intervention to improve initiation of tuberculosis preventive treatment: results from a follow-up study of the ACT4 randomized trial. EClinicalMedicine 2024; 71:102546. [PMID: 38586588 PMCID: PMC10998081 DOI: 10.1016/j.eclinm.2024.102546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/12/2023] [Revised: 01/24/2024] [Accepted: 02/29/2024] [Indexed: 04/09/2024] Open
Abstract
Background In a cluster randomized trial (clinicaltrials.gov: NCT02810678) a flexible but comprehensive health system intervention significantly increased the number of household contacts (HHC) identified and started on tuberculosis preventive treatment (TPT). A follow-up study was conducted one year later to test the hypotheses that these effects were sustained, and were reproducible with a simplified intervention. Methods We conducted a follow-up study from May 1, 2018 until April 30, 2019, as part of a multinational cluster randomized trial. Eight sites in 4 countries that had received the intervention in the original trial received no further intervention; eight other sites in the same countries that had not received the intervention (control sites in the original trial) now received a simplified version of the intervention. This consisted of repeated local evaluation of the Cascade of care for TB infection, and stakeholder decision making. The number of HHC identified and starting TPT were repeatedly measured at all 16 sites and expressed as rates per 100 newly diagnosed index TB patients. The sustained effect of the original intervention was estimated by comparing these rates after the intervention in the original trial with the last 6 months of the follow-up study. The reproducibility was estimated by comparing the pre-post intervention changes in rates at sites receiving the original intervention with the pre-post changes in rates at sites receiving the later, simplified intervention. Findings With regard to the sustained impact of the original intervention, compared to the original post-intervention period, the number of HHC identified and treated per 100 newly diagnosed TB patients was 10 more (95% confidence interval: 84 fewer to 105 more), and 1 fewer (95% CI: 22 fewer to 20 more) respectively up to 14 months after the end of the original intervention. With regard to the reproducibility of the simplified intervention, at sites that had initially served as control sites, the number of HHC identified and treated per 100 TB patients increased by 33 (95% CI: -32, 97), and 16 (-69, 100) from 3 months before, to up to 6 months after receiving a streamlined intervention, although differences were larger, and significant if the post-intervention results were compared to all pre-intervention periods. Interpretation Up to one year after it ended, a health system intervention resulted in sustained increases in the number of HHC identified and starting TPT. A simplified version of the intervention was associated with non-significant increases in the identification and treatment of HHC. Inferences are limited by potential bias due to other temporal effects, and the small number of study sites. Funding Funded by the Canadian Institutes of Health Research (Grant number 143350).
Collapse
Affiliation(s)
- Dick Menzies
- McGill International TB Centre, Montreal Chest Institute and Research Institute of the MUHC, Canada
- Department of Epidemiology & Biostatistics, McGill University, Canada
| | | | | | - Rovina Ruslami
- Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
| | - Menonli Adjobimey
- Centre National Hospitalier Universitaire de Pneumo-Phtisiologie de Cotonou, Benin
| | - Dina Fisher
- Department of Medicine, Cumming School of Medicine, University of Calgary, Canada
| | - Leila Barss
- Department of Medicine, Cumming School of Medicine, University of Calgary, Canada
| | - Nancy Bedingfield
- Department of Medicine, Cumming School of Medicine, University of Calgary, Canada
| | - Richard Long
- Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Canada
| | - Catherine Paulsen
- Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Canada
| | - James Johnston
- British Columbia Centre for Disease Control, Vancouver, Canada
- Department of Medicine, University of British Columbia, Vancouver, Canada
| | - Kamila Romanowski
- Department of Medicine, University of British Columbia, Vancouver, Canada
| | - Victoria J. Cook
- British Columbia Centre for Disease Control, Vancouver, Canada
- Department of Medicine, University of British Columbia, Vancouver, Canada
| | - Greg J. Fox
- Faculty of Medicine and Health, The University of Sydney, Sydney, Australia
| | - Thu Anh Nguyen
- Faculty of Medicine and Health, The University of Sydney, Sydney, Australia
| | - Chantal Valiquette
- McGill International TB Centre, Montreal Chest Institute and Research Institute of the MUHC, Canada
| | - Olivia Oxlade
- McGill International TB Centre, Montreal Chest Institute and Research Institute of the MUHC, Canada
- School of Population and Global Health, McGill University, Canada
| | - Federica Fregonese
- McGill International TB Centre, Montreal Chest Institute and Research Institute of the MUHC, Canada
| | - Andrea Benedetti
- McGill International TB Centre, Montreal Chest Institute and Research Institute of the MUHC, Canada
- Department of Epidemiology & Biostatistics, McGill University, Canada
| |
Collapse
|
2
|
Anderson L, Hopson B, Caudill C, Rocque BG, Blount J, Arynchyna-Smith A, Thrower J, Johnston J, Rozzelle C. Evaluation of multidisciplinary high-risk pregnancy clinic for myelomeningocele. Childs Nerv Syst 2024:10.1007/s00381-024-06337-4. [PMID: 38644383 DOI: 10.1007/s00381-024-06337-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/11/2024] [Accepted: 02/26/2024] [Indexed: 04/23/2024]
Abstract
INTRODUCTION A cross-sectional study retrospectively evaluating the perceived usefulness of attending a multi-disciplinary, roundtable, educational prenatal clinic for mothers expecting children with myelomeningocele is presented. METHODS Mothers who currently have children with SB completed a survey which evaluated their overall preparedness, spina bifida education, delivery plans, surgical expectations, and expectations in terms of quality of life and development. Open comments were also collected. Statistical analysis was performed to identify differences between those who attended prenatal counseling and those who did not. RESULTS Approximately half of these mothers received some form of prenatal SB counseling. Mothers who attended prenatal counseling reported that they felt more informed and prepared throughout their pregnancy, during the delivery of their child and during their initial hospital stay than mothers who did not. They reported that the roundtable discussions were beneficial, and the education they received was useful in helping them form accurate expectations and feel more at ease. CONCLUSION This suggests that prenatal counseling and the High-Risk Pregnancy Clinic (HRPC) provides perceived utility to families and mothers and that the HRPC is an effective method of providing prenatal counseling to mothers whose unborn children have been diagnosed with myelomeningocele.
Collapse
Affiliation(s)
- Luke Anderson
- Marnix E. Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Betsy Hopson
- Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
- Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, USA.
- Division of Pediatric Neurosurgery, University of Alabama at Birmingham, 1600 7th Ave S., Lowder 400, Birmingham, AL, USA.
| | - Caroline Caudill
- Division of Pediatric Neurosurgery, University of Alabama at Birmingham, 1600 7th Ave S., Lowder 400, Birmingham, AL, USA
| | - Brandon G Rocque
- Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, USA
- Division of Pediatric Neurosurgery, University of Alabama at Birmingham, 1600 7th Ave S., Lowder 400, Birmingham, AL, USA
| | - Jeffrey Blount
- Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, USA
- Division of Pediatric Neurosurgery, University of Alabama at Birmingham, 1600 7th Ave S., Lowder 400, Birmingham, AL, USA
| | - Anastasia Arynchyna-Smith
- Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, USA
- Division of Pediatric Neurosurgery, University of Alabama at Birmingham, 1600 7th Ave S., Lowder 400, Birmingham, AL, USA
| | - Jessica Thrower
- Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, USA
- Division of Pediatric Neurosurgery, University of Alabama at Birmingham, 1600 7th Ave S., Lowder 400, Birmingham, AL, USA
| | - James Johnston
- Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, USA
- Division of Pediatric Neurosurgery, University of Alabama at Birmingham, 1600 7th Ave S., Lowder 400, Birmingham, AL, USA
| | - Curtis Rozzelle
- Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, USA
- Division of Pediatric Neurosurgery, University of Alabama at Birmingham, 1600 7th Ave S., Lowder 400, Birmingham, AL, USA
| |
Collapse
|
3
|
Johnston J, Jeon H, Choi YY, Kim G, Chang HC, Myung NV, Wang Y. Stimulative piezoelectric nanofibrous scaffolds for enhanced small extracellular vesicle production in 3D cultures. bioRxiv 2024:2024.04.12.589114. [PMID: 38659930 PMCID: PMC11042190 DOI: 10.1101/2024.04.12.589114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/26/2024]
Abstract
Small extracellular vesicles (sEVs) have great promise as effective carriers for drug delivery. However, the challenges associated with the efficient production of sEVs hinder their clinical applications. Herein, we report a stimulative 3D culture platform for enhanced sEV production. The proposed platform consists of a piezoelectric nanofibrous scaffold (PES) coupled with acoustic stimulation to enhance sEV production of cells in a 3D biomimetic microenvironment. Combining cell stimulation with a 3D culture platform in this stimulative PES enables a 49 fold increase in the production rate per cell with minimal deviations in particle size and protein composition compared with standard 2D cultures. We find that the enhanced sEV production is attributable to the activation and upregulation of crucial sEV production steps through the synergistic effect of stimulation and the 3D microenvironment. Moreover, changes in cell morphology lead to cytoskeleton redistribution through cell matrix interactions in the 3D cultures. This in turn facilitates intracellular EV trafficking, which impacts the production rate. Overall, our work provides a promising 3D cell culture platform based on piezoelectric biomaterials for enhanced sEV production. This platform is expected to accelerate the potential use of sEVs for drug delivery and broad biomedical applications.
Collapse
|
4
|
Teh J, Biswas K, Waldvogel-Thurlow S, Broderick D, Clark ST, Johnston J, Wagner Mackenzie B, Douglas R. Paired qualitative and quantitative analysis of bacterial microcolonies in the tonsils of patients with tonsillar hyperplasia. Microbes Infect 2024:105317. [PMID: 38452852 DOI: 10.1016/j.micinf.2024.105317] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2023] [Revised: 02/03/2024] [Accepted: 02/29/2024] [Indexed: 03/09/2024]
Abstract
The discovery of bacterial microcolonies in tonsillar tissue of patients with tonsillar hyperplasia has raised the question of their role in provoking the local immune response. Tonsils collected from patients undergoing tonsillectomy were stained for three clinically relevant bacterial taxa and lymphocytes. The bacterial composition and abundance of microcolonies was investigated using a combination of laser-microdissection, amplicon sequencing and Droplet Digital polymerase chain reaction. Microcolonies were detected in most samples (32/35) with a high prevalence of Haemophilus influenzae (78% of samples). B and T cell lymphocytes were significantly higher in the epithelium adjacent to microcolonies compared to epithelium distal to microcolonies. Furthermore, significant positive and negative correlations were identified between bacterial taxa and lymphocytes. Genus Streptococcus, which includes Group A Streptococcus (traditionally described as the main pathogen of tonsillar hyperplasia), was found in low abundance in this study. These results suggest other potential pathogens may be involved in stimulating the local immune response leading to tonsillar hyperplasia.
Collapse
Affiliation(s)
- Jackson Teh
- Department of Surgery, School of Medicine, The University of Auckland, Auckland, 1023, New Zealand
| | - Kristi Biswas
- Department of Surgery, School of Medicine, The University of Auckland, Auckland, 1023, New Zealand.
| | - Sharon Waldvogel-Thurlow
- Department of Surgery, School of Medicine, The University of Auckland, Auckland, 1023, New Zealand
| | - David Broderick
- Department of Surgery, School of Medicine, The University of Auckland, Auckland, 1023, New Zealand
| | - Sita Tarini Clark
- Te Whatu Ora - Te Toka Tumai Auckland, Health New Zealand, Auckland, 1142, New Zealand
| | - James Johnston
- Department of Surgery, School of Medicine, The University of Auckland, Auckland, 1023, New Zealand; Te Whatu Ora - Te Toka Tumai Auckland, Health New Zealand, Auckland, 1142, New Zealand
| | - Brett Wagner Mackenzie
- Department of Surgery, School of Medicine, The University of Auckland, Auckland, 1023, New Zealand
| | - Richard Douglas
- Department of Surgery, School of Medicine, The University of Auckland, Auckland, 1023, New Zealand; Te Whatu Ora - Te Toka Tumai Auckland, Health New Zealand, Auckland, 1142, New Zealand
| |
Collapse
|
5
|
Wedner HJ, Fujisawa T, Guilbert TW, Ikeda M, Mehta V, Tam JS, Lukka PB, Asimus S, Durżyński T, Johnston J, White WI, Shah M, Werkström V, Jison ML. Benralizumab in children with severe eosinophilic asthma: Pharmacokinetics and long-term safety (TATE study). Pediatr Allergy Immunol 2024; 35:e14092. [PMID: 38491795 DOI: 10.1111/pai.14092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/03/2023] [Revised: 02/01/2024] [Accepted: 02/05/2024] [Indexed: 03/18/2024]
Abstract
BACKGROUND Benralizumab is an anti-interleukin-5 receptor α monoclonal antibody approved as an add-on maintenance treatment for patients with uncontrolled severe asthma. Prior Phase 3 studies have evaluated benralizumab in patients aged ≥12 years with severe uncontrolled asthma. The TATE study evaluated the pharmacokinetics (PK), pharmacodynamics (PD), and safety of benralizumab treatment in children. METHODS TATE was an open-label, Phase 3 study of benralizumab in children aged 6-11 years from the United States and Japan (plus participants aged 12-14 years from Japan) with severe eosinophilic asthma. Participants received benralizumab 10/30 mg according to weight (<35/≥35 kg). Primary endpoints included maximum serum concentration (Cmax ), clearance, half-life (t1/2 ), and blood eosinophil count. Clearance and t1/2 were derived from a population PK (popPK) analysis. Safety and tolerability were also assessed. RESULTS Twenty-eight children aged 6-11 years were included, with an additional two participants from Japan aged 12-14 years also included in the popPK analysis. Mean Cmax was 1901.2 and 3118.7 ng/mL in the 10 mg/<35 kg and 30 mg/≥35 kg groups, respectively. Clearance was 0.257, and mean t1/2 was 14.5 days. Near-complete depletion of blood eosinophils was shown across dose/weight groups. Exploratory efficacy analyses found numerical improvements in mean FEV1 , mean ACQ-IA, patient/clinician global impression of change, and exacerbation rates. Adverse events occurred in 22/28 (78.6%) of participants; none led to discontinuation/death. CONCLUSION PK, PD, and safety data support long-term benralizumab in children with severe eosinophilic asthma, and were similar to findings in adolescents and adults. TRIAL REGISTRATION ClinicalTrials.gov-ID: NCT04305405.
Collapse
Affiliation(s)
- H James Wedner
- Division of Allergy and Immunology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
| | - Takao Fujisawa
- Allergy Center, National Hospital Organization Mie National Hospital, Tsu, Japan
| | - Theresa W Guilbert
- Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
| | - Masanori Ikeda
- Okayama University School of Medicine, Okayama, Japan
- Department of Pediatrics, Fukuyama Municipal Hospital, Fukuyama, Hiroshima, Japan
| | - Vinay Mehta
- Allergy, Asthma and Immunology Associates, Lincoln, Nebraska, USA
| | - Jonathan S Tam
- Division of Clinical Immunology and Allergy, Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, California, USA
| | - Pradeep B Lukka
- Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gaithersburg, Maryland, USA
| | - Sara Asimus
- Clinical Pharmacology & Quantitative Pharmacology, R&D, AstraZeneca, Gothenburg, Sweden
| | - Tomasz Durżyński
- Late R&I Clinical Development, BioPharmaceuticals R&D, AstraZeneca, Warsaw, Poland
| | - James Johnston
- Biostatistics, R&I Biologics and Vaccine Products, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
| | - Wendy I White
- Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gaithersburg, Maryland, USA
| | - Mihir Shah
- Late R&I Clinical Development, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA
| | - Viktoria Werkström
- Late R&I Clinical Development, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
| | - Maria L Jison
- Late R&I Clinical Development, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA
| |
Collapse
|
6
|
Prince EW, Apps JR, Jeang J, Chee K, Medlin S, Jackson EM, Dudley R, Limbrick D, Naftel R, Johnston J, Feldstein N, Prolo LM, Ginn K, Niazi T, Smith A, Kilburn L, Chern J, Leonard J, Lam S, Hersh DS, Gonzalez-Meljem JM, Amani V, Donson AM, Mitra SS, Bandohpadhayay P, Martinez-Barbera JP, Hankinson TC. Unraveling the Complexity of the Senescence-Associated Secretory Phenotype in Adamantinomatous Craniopharyngioma Using Multi-Modal Machine Learning Analysis. Neuro Oncol 2024:noae015. [PMID: 38334125 DOI: 10.1093/neuonc/noae015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2023] [Indexed: 02/10/2024] Open
Abstract
BACKGROUND Cellular senescence can have positive and negative effects on the body, including aiding in damage repair and facilitating tumor growth. Adamantinomatous Craniopharyngioma (ACP), the most common pediatric sellar/suprasellar brain tumor, poses significant treatment challenges. Recent studies suggest that senescent cells in ACP tumors may contribute to tumor growth and invasion by releasing a Senesecence-Associated Secretory Phenotype (SASP). However, a detailed analysis of these characteristics has yet to be completed. METHODS We analyzed primary tissue samples from ACP patients using single-cell, single-nuclei, and spatial RNA Sequencing. We performed various analyses, including gene expression clustering, inferred senescence cells from gene expression, and conducted cytokine signaling inference. We utilized LASSO to select essential gene expression pathways associated with senescence. Finally, we validated our findings through immunostaining. RESULTS We observed significant diversity in gene expression and tissue structure. Key factors such as NFKB, RELA, and SP1 are essential in regulating gene expression, while senescence markers are present throughout the tissue. SPP1 is the most significant cytokine signaling network among ACP cells, while the Wnt signaling pathway predominantly occurs between epithelial and glial cells. Our research has identified links between senescence-associated features and pathways, such as PI3K/Akt/mTOR, MYC, FZD, and Hedgehog, with increased P53 expression associated with senescence in these cells. CONCLUSIONS A complex interplay between cellular senescence, cytokine signaling, and gene expression pathways underlies ACP development. Further research is crucial to understand how these elements interact to create novel therapeutic approaches for patients with ACP.
Collapse
Affiliation(s)
- Eric W Prince
- Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
- Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO, USA
- Morgan Adams Foundation for Pediatric Brain Tumor Research Program, Aurora, CO, USA
| | - John R Apps
- Oncology Department, Birmingham Women's and Children's NHS Foundation Trust, Birmingham B4 6NH, UK
| | - John Jeang
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA
| | - Keanu Chee
- Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
- Morgan Adams Foundation for Pediatric Brain Tumor Research Program, Aurora, CO, USA
| | - Stephen Medlin
- Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
- Morgan Adams Foundation for Pediatric Brain Tumor Research Program, Aurora, CO, USA
| | - Eric M Jackson
- Johns Hopkins University School of Medicine, Department of Neurosurgery, Baltimore, USA
| | - Roy Dudley
- McGill University, Department of Neurosurgery, Montreal, CAN
| | - David Limbrick
- Washington University School of Medicine, Department of Pediatrics, St. Louis, USA; Washington University School of Medicine, Department of Neurosurgery, St. Louis, USA
| | - Robert Naftel
- Vanderbilt University Medical Center, Monroe Carell Jr. Children's Hospital at Vanderbilt, Department of Neurological Surgery, Nashville, USA
| | - James Johnston
- University of Alabama at Birmingham, Department of Neurosurgery, Division of Pediatric Neurosurgery, Birmingham, USA
| | - Neil Feldstein
- Department of Neurosurgery, Columbia University Medical Center, New York, NY, USA
| | - Laura M Prolo
- Stanford University School of Medicine, Lucile Packard Children's Hospital, Department of Neurosurgery, Division of Pediatric Neurosurgery, Palo Alto, USA
| | - Kevin Ginn
- Children's Mercy Hospital, The Division of Pediatric Hematology and Oncology, the Department of Pediatrics, Kansas City, USA
| | - Toba Niazi
- Nicklaus Children's Hospital, Department of Pediatric Neurosurgery, Miami, USA
| | - Amy Smith
- Arnold Palmer Hospital, Department of Pediatric Hematology-Oncology, Orlando, USA
| | - Lindsay Kilburn
- Children's National Health System, Center for Cancer and Blood Disorders, Washington, DC, USA; Children's National Health System, Brain Tumor Institute, Washington, DC, USA
| | - Joshua Chern
- Emory University School of Medicine, Department of Pediatrics and Neurosurgery, Atlanta, USA; Children's Healthcare of Atlanta, Department of Pediatric Neurosurgery, Atlanta, USA
| | - Jeffrey Leonard
- Nationwide Children's Hospital, Division of Pediatric Neurosurgery, Columbus, USA
| | - Sandi Lam
- Division of Neurosurgery, Ann & Robert H. Lurie Children's Hospital of Chicago, Illinois
| | - David S Hersh
- Division of Neurosurgery, Connecticut Children's, Hartford, Connecticut, USA
| | | | - Vladimir Amani
- Morgan Adams Foundation for Pediatric Brain Tumor Research Program, Aurora, CO, USA
| | - Andrew M Donson
- Morgan Adams Foundation for Pediatric Brain Tumor Research Program, Aurora, CO, USA
| | - Siddhartha S Mitra
- Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
- Morgan Adams Foundation for Pediatric Brain Tumor Research Program, Aurora, CO, USA
| | | | - Juan Pedro Martinez-Barbera
- Developmental Biology and Cancer, Birth Defects Research Centre, GOS Institute of Child Health, University College London, London, WC1N 1EH, UK
| | - Todd C Hankinson
- Department of Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
- Morgan Adams Foundation for Pediatric Brain Tumor Research Program, Aurora, CO, USA
| |
Collapse
|
7
|
Alsdurf H, Benedetti A, Buu TN, Adjobimey M, Cook VJ, Fisher D, Fox G, Fregonese F, Hadisoemarto P, Johnston J, Long R, Obeng J, Oxlade O, Ruslami R, Schwartzman K, Strumpf E, Menzies D. Human resource implications of expanding latent tuberculosis patient care activities. Front Med (Lausanne) 2024; 10:1265476. [PMID: 38283039 PMCID: PMC10811144 DOI: 10.3389/fmed.2023.1265476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2023] [Accepted: 12/26/2023] [Indexed: 01/30/2024] Open
Abstract
Introduction The World Health Organization (WHO) declared increasing services for latent tuberculosis infection (LTBI) a priority to eliminate tuberculosis (TB) by 2035. Yet, there is little information about thehuman resource needs required to implement LTBI treatment scale-up. Our study aimed to estimate the change in healthcare workers (HCW) time spent on different patient care activities, following an intervention to strengthen LTBI services. Methods We conducted a time and motion (TAM) study, observing HCW throughout a typical workday before and after the intervention (Evaluation and Strengthening phases, respectively) at 24 health facilities in five countries. The precise time spent on pre-specified categories of work activities was recorded. Time spent on direct patient care was subcategorized as relating to one of three conditions: LTBI, active or suspected TB, and non-TB (i.e., patients with any other medical condition). A linear mixed model (LMM) was fit to estimate the change in HCW time following the intervention. Results A total of 140 and 143 HCW participated in the TAMs during the Evaluation and Strengthening phases, respectively. Results from intervention facilities showed an increase of 9% (95% CI: 3%, 15%) in the proportion of HCW time spent on LTBI-related services, but with a corresponding change of -11% (95% CI: -21%, -1%) on active TB services. There was no change in the proportion of time spent on LTBI care in control facilities; this remained low in both phases of the study. Discussion Our findings suggest that additional HCW personnel will be required for expansion of LTBI services to ensure that this expansion does not reduce the time available for care of active TB patients.
Collapse
Affiliation(s)
- Hannah Alsdurf
- Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada
- McGill International TB Centre, McGill University, Montreal, QC, Canada
| | - Andrea Benedetti
- Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada
- McGill International TB Centre, McGill University, Montreal, QC, Canada
| | - Tran Ngoc Buu
- Woolcock Institute of Medical Research, Hanoi, Vietnam
| | - Menonli Adjobimey
- Programme National Contre la Tuberculose, Centre National Hospitalier Universitaire de Pneumo-Phtisiologie, Cotonou, Benin
| | - Victoria J. Cook
- Provincial Tuberculosis Services, British Columbia Centre for Disease Control, Vancouver, BC, Canada
- Department of Medicine, University of British Columbia, Vancouver, BC, Canada
| | - Dina Fisher
- Division of Respiratory Medicine, University of Calgary, Calgary, AB, Canada
| | - Gregory Fox
- The University of Sydney Central Clinical School, The Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia
| | | | - Panji Hadisoemarto
- Department of Public Health, Faculty of Medicine, TB-HIV Research Center, Universitas Padjadjaran, Bandung, Indonesia
| | - James Johnston
- Provincial Tuberculosis Services, British Columbia Centre for Disease Control, Vancouver, BC, Canada
| | - Richard Long
- Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
| | - Joseph Obeng
- Chest Clinic, Komfo Anokye Teaching Hospital, Kumasi, Ghana
| | - Olivia Oxlade
- McGill International TB Centre, McGill University, Montreal, QC, Canada
- Respiratory Epidemiology and Clinical Research Unit (RECRU), McGill University, Montreal, QC, Canada
| | - Rovina Ruslami
- Department of Biomedical Sciences, Division of Pharmacology and Therapy, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
| | - Kevin Schwartzman
- Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada
- McGill International TB Centre, McGill University, Montreal, QC, Canada
- Respiratory Epidemiology and Clinical Research Unit (RECRU), McGill University, Montreal, QC, Canada
| | - Erin Strumpf
- Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada
| | - Dick Menzies
- Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada
- McGill International TB Centre, McGill University, Montreal, QC, Canada
- Respiratory Epidemiology and Clinical Research Unit (RECRU), McGill University, Montreal, QC, Canada
| |
Collapse
|
8
|
Johnston J. Henry S. Pennypacker, 1937-2023. J Appl Behav Anal 2024; 57:25-26. [PMID: 37997474 DOI: 10.1002/jaba.1041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2023] [Accepted: 11/01/2023] [Indexed: 11/25/2023]
Affiliation(s)
- James Johnston
- Auburn University, Department of Psychological Sciences, Auburn, Alabama, USA
| |
Collapse
|
9
|
Adams DQ, Alduino C, Alfonso K, Avignone FT, Azzolini O, Bari G, Bellini F, Benato G, Biassoni M, Branca A, Brofferio C, Bucci C, Camilleri J, Caminata A, Campani A, Canonica L, Cao XG, Capelli S, Cappelli L, Cardani L, Carniti P, Casali N, Chiesa D, Clemenza M, Copello S, Cosmelli C, Cremonesi O, Creswick RJ, D'Addabbo A, Dafinei I, Davis CJ, Dell'Oro S, Di Domizio S, Dompè V, Fang DQ, Fantini G, Faverzani M, Ferri E, Ferroni F, Fiorini E, Franceschi MA, Freedman SJ, Fu SH, Fujikawa BK, Giachero A, Gironi L, Giuliani A, Gorla P, Gotti C, Gutierrez TD, Han K, Heeger KM, Huang RG, Huang HZ, Johnston J, Keppel G, Kolomensky YG, Ligi C, Ma L, Ma YG, Marini L, Maruyama RH, Mayer D, Mei Y, Moggi N, Morganti S, Napolitano T, Nastasi M, Nikkel J, Nones C, Norman EB, Nucciotti A, Nutini I, O'Donnell T, Ouellet JL, Pagan S, Pagliarone CE, Pagnanini L, Pallavicini M, Pattavina L, Pavan M, Pessina G, Pettinacci V, Pira C, Pirro S, Pozzi S, Previtali E, Puiu A, Rosenfeld C, Rusconi C, Sakai M, Sangiorgio S, Schmidt B, Scielzo ND, Sharma V, Singh V, Sisti M, Speller D, Surukuchi PT, Taffarello L, Terranova F, Tomei C, Vetter KJ, Vignati M, Wagaarachchi SL, Wang BS, Welliver B, Wilson J, Wilson K, Winslow LA, Zimmermann S, Zucchelli S. Erratum: Measurement of the 2νββ Decay Half-Life of ^{130}Te with CUORE [Phys. Rev. Lett. 126, 171801 (2021)]. Phys Rev Lett 2023; 131:249902. [PMID: 38181163 DOI: 10.1103/physrevlett.131.249902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/10/2023] [Indexed: 01/07/2024]
Abstract
This corrects the article DOI: 10.1103/PhysRevLett.126.171801.
Collapse
|
10
|
Pavan C, Jin J, Jong S, Strbenac D, Davis RL, Sue CM, Johnston J, Lynch T, Halliday G, Kirik D, Parish CL, Thompson LH, Ovchinnikov DA. Generation of the iPSC line FINi002-A from a male Parkinson's disease patient carrying compound heterozygous mutations in the PRKN gene. Stem Cell Res 2023; 73:103211. [PMID: 37890334 DOI: 10.1016/j.scr.2023.103211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/16/2023] [Accepted: 09/21/2023] [Indexed: 10/29/2023] Open
Abstract
The most common cause of autosomal recessive familial Parkinson's disease (PD) are mutations in the PRKN/PARK2 gene encoding an E3 ubiquitin protein-ligase PARKIN. We report the generation of an iPSC cell line from the fibroblasts of a male PD patient carrying a common missense variant in exon 7 (p.Arg275Trp), and a 133 kb deletion encompassing exon 8, using transiently-present Sendai virus. The established line displays typical human primed iPSC morphology and expression of pluripotency-associated markers, normal karyotype without SNP array-detectable copy number variations and can give rise to derivatives of all three embryonic germ layers. We envisage the usefulness of this iPSC line, carrying a common and well-studied missense mutation in the RING1 domain of the PARKIN protein, for the elucidation of PARKIN-dependent mechanisms of PD using in vitro and in vivo models.
Collapse
Affiliation(s)
- C Pavan
- The Florey Institute for Neuroscience and Mental Health, University of Melbourne, Melbourne VIC 3010 Australia
| | - J Jin
- The Florey Institute for Neuroscience and Mental Health, University of Melbourne, Melbourne VIC 3010 Australia
| | - S Jong
- The Florey Institute for Neuroscience and Mental Health, University of Melbourne, Melbourne VIC 3010 Australia
| | - D Strbenac
- University of Sydney, Sydney, NSW 2006, Australia
| | - R L Davis
- University of Sydney, Sydney, NSW 2006, Australia
| | - C M Sue
- Neuroscience Research Australia and University of New South Wales, Sydney, NSW 2031, Australia
| | | | - T Lynch
- Mater Misericordiae University Hospital, Dublin, D07 R2WY, Ireland
| | - G Halliday
- University of Sydney, Sydney, NSW 2006, Australia
| | - D Kirik
- University of Sydney, Sydney, NSW 2006, Australia; Lund University, Lund, 22184 Sweden
| | - C L Parish
- The Florey Institute for Neuroscience and Mental Health, University of Melbourne, Melbourne VIC 3010 Australia
| | - L H Thompson
- The Florey Institute for Neuroscience and Mental Health, University of Melbourne, Melbourne VIC 3010 Australia; University of Sydney, Sydney, NSW 2006, Australia.
| | - D A Ovchinnikov
- The Florey Institute for Neuroscience and Mental Health, University of Melbourne, Melbourne VIC 3010 Australia
| |
Collapse
|
11
|
Johnston J, O'Rourke C, Mills A. Photoinduced absorption spectroscopy (PIAS) study of water and chloride oxidation by a WO 3 photoanode in acidic solution. Phys Chem Chem Phys 2023; 25:31825-31835. [PMID: 37966122 DOI: 10.1039/d3cp03167e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2023]
Abstract
The mechanisms of water and chloride oxidation by a WO3 photoanode are probed by photoinduced absorption spectroscopy (PIAS) coupled with transient photocurrent (TC) measurements. Linear sweep voltammograms (LSVs) and incident photon to current efficiencies (IPCEs) are obtained, in the water oxidation electrolyte (1 M HClO4) and chloride oxidation electrolyte (3.5 M NaCl in 1 M HClO4). Other work shows that the faradaic efficiency of water oxidation to O2 in 1 M HClO4 is ca. 1.0, and that for chloride oxidation to Cl2 in 3.5 M NaCl plus 1 M HClO4 is ca. 0.62. The PIAS/TC data reveals a 0.4 order dependency of the rate of water oxidation on the steady state concentration of photogenerated surface holes, [hs+]ss, and an approximately first order dependency of the rate of chloride oxidation on [hs+]ss. Associated mechanisms and rate determining steps for water and chloride oxidation at the photoanode surface that account for these reaction orders are proposed.
Collapse
Affiliation(s)
- James Johnston
- School of Chemistry and Chemical Engineering, Queens University Belfast, Stranmillis Road, Belfast, BT9 5AG, UK.
| | - Christopher O'Rourke
- School of Chemistry and Chemical Engineering, Queens University Belfast, Stranmillis Road, Belfast, BT9 5AG, UK.
| | - Andrew Mills
- School of Chemistry and Chemical Engineering, Queens University Belfast, Stranmillis Road, Belfast, BT9 5AG, UK.
| |
Collapse
|
12
|
Mackay G, Johnston J, Mallick S, Khanijow V. Multinodal Cervical Angiomyomatous Hamartoma. Int J Surg Pathol 2023:10668969231212429. [PMID: 38124308 DOI: 10.1177/10668969231212429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2023]
Abstract
Angiomyomatous hamartoma (AMH) is a rare benign lesion of the lymph nodes. Angiomyomatous hamartoma tends to be found in inguinal lymph nodes, and usually in a single lymph node. We present a rare care case of a 53-year-old presenting with a neck lump, found to be AMH involving multiple lymph nodes in her neck. To our knowledge, this is the first case presenting with multiple nodes in this location. There are a limited number of case reports describing magnetic resonance imaging (MRI) features of AMH lesions located in inguinal and head and neck regions. Our MRI findings revealed the mass had intermediate T1 enhancement, high T2 signal enhancement, and high post-gadolinium enhancement and fat saturation of the lesion. Angiomyomatous hamartoma is a histological diagnosis, distinguished from other similar nodal vascular lesions by a number of key features: including the presence of central nodal distribution, muscular blood vessel walls, adipose tissue, and HMB45 negative staining. Early recognition of this benign lesion may have implications for a patient's clinical course and surgical requirements.
Collapse
Affiliation(s)
- Georgia Mackay
- Department of Health Science, The University of Auckland Faculty of Medical and Health Sciences, Auckland, New Zealand
| | - James Johnston
- Department of Surgery, The University of Auckland, Auckland, New Zealand
| | - Sameer Mallick
- Department of ORL Head and Neck Surgery, Auckland District Health Board, Auckland, New Zealand
| | - Vinod Khanijow
- Department of Pathology, Auckland City Hospital, Auckland, New Zealand
| |
Collapse
|
13
|
O'Dell JC, Halimeh BN, Johnston J, McCoy CC, Winfield RD, Guidry CA. Antibiotic Initiation Timing and Mortality in Trauma Patients With Ventilator-Associated Pneumonia. Am Surg 2023; 89:4740-4746. [PMID: 36196032 DOI: 10.1177/00031348221129518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
BACKGROUND Early antibiotic initiation is considered a cornerstone in the management of ventilator-associated pneumonia (VAP). However, recent data suggests that early antibiotic initiation may not be necessary in all cases. Additionally, the benefits of early antibiotic administration for infection have not been studied in a dedicated trauma population. This study's aim was to evaluate the impact of antibiotic administration timing on in-hospital mortality in trauma patients with VAP. METHODS This retrospective case-control study identified all trauma patients at a single level 1 academic trauma center from 2016 to 2020. Patients with a TQIP-defined VAP were included and stratified into 2 subgroups by in-hospital mortality. Time interval between airway culture and antibiotic initiation was gathered. Baseline measures of injury and illness severity were collected. Univariate analysis of the data was performed. RESULTS Forty-five patients met inclusion criteria. Overall, 80% of patients survived admission (n = 36) and 20% of patients did not survive admission (n = 9). There were no significant differences in baseline characteristics or cultured organism between survivors and non-survivors. The median time interval between airway culture and antibiotic initiation was 2 hours (IQR 0-4.5) for survivors, and 0 hours (IQR 0-0) for non-survivors (P = .07). Antibiotics were administered within 1 hour of airway culture for 33.3% of survivors, and 77.8% of non-survivors (P = .02). CONCLUSIONS In a population of trauma patients with VAP, survivors had antibiotics initiated in more delayed fashion than non-survivors. These findings question the primacy of early antibiotic administration for suspected infection.
Collapse
Affiliation(s)
- Jacob C O'Dell
- Division of Trauma Critical Care and Acute Care Surgery, Department of Surgery, University of Kansas Medical Center, Kansas City, KS, USA
| | - Bachar N Halimeh
- Department of Surgery, Boston University Medical Center, Boston, MA, USA
| | - James Johnston
- Division of Trauma Critical Care and Acute Care Surgery, Department of Surgery, University of Kansas Medical Center, Kansas City, KS, USA
| | - C Cameron McCoy
- Division of Trauma Critical Care and Acute Care Surgery, Department of Surgery, University of Kansas Medical Center, Kansas City, KS, USA
| | - Robert D Winfield
- Division of Trauma Critical Care and Acute Care Surgery, Department of Surgery, University of Kansas Medical Center, Kansas City, KS, USA
| | - Christopher A Guidry
- Division of Trauma Critical Care and Acute Care Surgery, Department of Surgery, University of Kansas Medical Center, Kansas City, KS, USA
| |
Collapse
|
14
|
Augier C, Barabash AS, Bellini F, Benato G, Beretta M, Bergé L, Billard J, Borovlev YA, Cardani L, Casali N, Cazes A, Celi E, Chapellier M, Chiesa D, Dafinei I, Danevich FA, De Jesus M, Dixon T, Dumoulin L, Eitel K, Ferri F, Fujikawa BK, Gascon J, Gironi L, Giuliani A, Grigorieva VD, Gros M, Helis DL, Huang HZ, Huang R, Imbert L, Johnston J, Juillard A, Khalife H, Kleifges M, Kobychev VV, Kolomensky YG, Konovalov SI, Kotila J, Loaiza P, Ma L, Makarov EP, de Marcillac P, Mariam R, Marini L, Marnieros S, Navick XF, Nones C, Norman EB, Olivieri E, Ouellet JL, Pagnanini L, Pattavina L, Paul B, Pavan M, Peng H, Pessina G, Pirro S, Poda DV, Polischuk OG, Pozzi S, Previtali E, Redon T, Rojas A, Rozov S, Sanglard V, Scarpaci JA, Schmidt B, Shen Y, Shlegel VN, Šimkovic F, Singh V, Tomei C, Tretyak VI, Umatov VI, Vagneron L, Velázquez M, Ware B, Welliver B, Winslow L, Xue M, Yakushev E, Zarytskyy M, Zolotarova AS. Measurement of the 2νββ Decay Rate and Spectral Shape of ^{100}Mo from the CUPID-Mo Experiment. Phys Rev Lett 2023; 131:162501. [PMID: 37925694 DOI: 10.1103/physrevlett.131.162501] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/26/2023] [Revised: 08/29/2023] [Accepted: 09/21/2023] [Indexed: 11/07/2023]
Abstract
Neutrinoless double beta decay (0νββ) is a yet unobserved nuclear process that would demonstrate Lepton number violation, a clear evidence of beyond standard model physics. The process two neutrino double beta decay (2νββ) is allowed by the standard model and has been measured in numerous experiments. In this Letter, we report a measurement of 2νββ decay half-life of ^{100}Mo to the ground state of ^{100}Ru of [7.07±0.02(stat)±0.11(syst)]×10^{18} yr by the CUPID-Mo experiment. With a relative precision of ±1.6% this is the most precise measurement to date of a 2νββ decay rate in ^{100}Mo. In addition, we constrain higher-order corrections to the spectral shape, which provides complementary nuclear structure information. We report a novel measurement of the shape factor ξ_{3,1}=0.45±0.03(stat)±0.05(syst) based on a constraint on the ratio of higher-order terms from theory, which can be reliably calculated. This is compared to theoretical predictions for different nuclear models. We also extract the first value for the effective axial vector coupling constant obtained from a spectral shape study of 2νββ decay.
Collapse
Affiliation(s)
- C Augier
- Univ Lyon, Université Lyon 1, CNRS/IN2P3, IP2I-Lyon, F-69622 Villeurbanne, France
| | - A S Barabash
- National Research Centre "Kurchatov Institute," Kurchatov Complex of Theoretical and Experimental Physics, 117218 Moscow, Russia
| | - F Bellini
- Dipartimento di Fisica, Sapienza Università di Roma, Piazzale Aldo Moro 2, I-00185 Rome, Italy
- INFN, Sezione di Roma, P.le Aldo Moro 2, I-00185 Rome, Italy
| | - G Benato
- INFN, Laboratori Nazionali del Gran Sasso, I-67100 Assergi (AQ), Italy
- INFN, Gran Sasso Science Institute, I-67100 L'Aquila, Italy
| | - M Beretta
- University of California, Berkeley, California 94720, USA
| | - L Bergé
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - J Billard
- Univ Lyon, Université Lyon 1, CNRS/IN2P3, IP2I-Lyon, F-69622 Villeurbanne, France
| | - Yu A Borovlev
- Nikolaev Institute of Inorganic Chemistry, 630090 Novosibirsk, Russia
| | - L Cardani
- INFN, Sezione di Roma, P.le Aldo Moro 2, I-00185 Rome, Italy
| | - N Casali
- INFN, Sezione di Roma, P.le Aldo Moro 2, I-00185 Rome, Italy
| | - A Cazes
- Univ Lyon, Université Lyon 1, CNRS/IN2P3, IP2I-Lyon, F-69622 Villeurbanne, France
| | - E Celi
- INFN, Laboratori Nazionali del Gran Sasso, I-67100 Assergi (AQ), Italy
- INFN, Gran Sasso Science Institute, I-67100 L'Aquila, Italy
| | - M Chapellier
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - D Chiesa
- Dipartimento di Fisica, Università di Milano-Bicocca, I-20126 Milano, Italy
- INFN, Sezione di Milano-Bicocca, I-20126 Milano, Italy
| | - I Dafinei
- INFN, Sezione di Roma, P.le Aldo Moro 2, I-00185 Rome, Italy
| | - F A Danevich
- Institute for Nuclear Research of NASU, 03028 Kyiv, Ukraine
- INFN, Sezione di Roma Tor Vergata, Via della Ricerca Scientifica 1, I-00133 Rome, Italy
| | - M De Jesus
- Univ Lyon, Université Lyon 1, CNRS/IN2P3, IP2I-Lyon, F-69622 Villeurbanne, France
| | - T Dixon
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - L Dumoulin
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - K Eitel
- Karlsruhe Institute of Technology, Institute for Astroparticle Physics, 76021 Karlsruhe, Germany
| | - F Ferri
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - B K Fujikawa
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - J Gascon
- Univ Lyon, Université Lyon 1, CNRS/IN2P3, IP2I-Lyon, F-69622 Villeurbanne, France
| | - L Gironi
- Dipartimento di Fisica, Università di Milano-Bicocca, I-20126 Milano, Italy
- INFN, Sezione di Milano-Bicocca, I-20126 Milano, Italy
| | - A Giuliani
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - V D Grigorieva
- Nikolaev Institute of Inorganic Chemistry, 630090 Novosibirsk, Russia
| | - M Gros
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - D L Helis
- INFN, Laboratori Nazionali del Gran Sasso, I-67100 Assergi (AQ), Italy
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - H Z Huang
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE), Fudan University, Shanghai 200433, People's Republic of China
| | - R Huang
- University of California, Berkeley, California 94720, USA
| | - L Imbert
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - J Johnston
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - A Juillard
- Univ Lyon, Université Lyon 1, CNRS/IN2P3, IP2I-Lyon, F-69622 Villeurbanne, France
| | - H Khalife
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - M Kleifges
- Karlsruhe Institute of Technology, Institute for Data Processing and Electronics, 76021 Karlsruhe, Germany
| | - V V Kobychev
- Institute for Nuclear Research of NASU, 03028 Kyiv, Ukraine
| | - Yu G Kolomensky
- University of California, Berkeley, California 94720, USA
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - S I Konovalov
- National Research Centre Kurchatov Institute, Institute of Theoretical and Experimental Physics, 117218 Moscow, Russia
| | - J Kotila
- Department of Physics, University of Jyväskylä, P.O. Box 35, FI-40014 Jyväskylä, Finland
- Finnish Institute for Educational Research, University of Jyväskylä, P.O. Box 35, FI-40014 Jyvaäskylä, Finland
- Center for Theoretical Physics, Sloane Physics Laboratory, Yale University, New Haven, Connecticut 06520-8120, USA
| | - P Loaiza
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - L Ma
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE), Fudan University, Shanghai 200433, People's Republic of China
| | - E P Makarov
- Nikolaev Institute of Inorganic Chemistry, 630090 Novosibirsk, Russia
| | - P de Marcillac
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - R Mariam
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - L Marini
- INFN, Laboratori Nazionali del Gran Sasso, I-67100 Assergi (AQ), Italy
- University of California, Berkeley, California 94720, USA
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - S Marnieros
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - X-F Navick
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - C Nones
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - E B Norman
- University of California, Berkeley, California 94720, USA
| | - E Olivieri
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - J L Ouellet
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - L Pagnanini
- INFN, Laboratori Nazionali del Gran Sasso, I-67100 Assergi (AQ), Italy
- INFN, Gran Sasso Science Institute, I-67100 L'Aquila, Italy
| | - L Pattavina
- INFN, Laboratori Nazionali del Gran Sasso, I-67100 Assergi (AQ), Italy
- Physik Department, Technische Universität München, Garching D-85748, Germany
| | - B Paul
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - M Pavan
- Dipartimento di Fisica, Università di Milano-Bicocca, I-20126 Milano, Italy
- INFN, Sezione di Milano-Bicocca, I-20126 Milano, Italy
| | - H Peng
- Department of Modern Physics, University of Science and Technology of China, Hefei 230027, People's Republic of China
| | - G Pessina
- INFN, Sezione di Milano-Bicocca, I-20126 Milano, Italy
| | - S Pirro
- INFN, Laboratori Nazionali del Gran Sasso, I-67100 Assergi (AQ), Italy
| | - D V Poda
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - O G Polischuk
- INFN, Sezione di Roma, P.le Aldo Moro 2, I-00185 Rome, Italy
- Institute for Nuclear Research of NASU, 03028 Kyiv, Ukraine
| | - S Pozzi
- INFN, Sezione di Milano-Bicocca, I-20126 Milano, Italy
| | - E Previtali
- Dipartimento di Fisica, Università di Milano-Bicocca, I-20126 Milano, Italy
- INFN, Sezione di Milano-Bicocca, I-20126 Milano, Italy
| | - Th Redon
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - A Rojas
- LSM, Laboratoire Souterrain de Modane, 73500 Modane, France
| | - S Rozov
- Laboratory of Nuclear Problems, JINR, 141980 Dubna, Moscow region, Russia
| | - V Sanglard
- Univ Lyon, Université Lyon 1, CNRS/IN2P3, IP2I-Lyon, F-69622 Villeurbanne, France
| | - J A Scarpaci
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - B Schmidt
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - Y Shen
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE), Fudan University, Shanghai 200433, People's Republic of China
| | - V N Shlegel
- Nikolaev Institute of Inorganic Chemistry, 630090 Novosibirsk, Russia
| | - F Šimkovic
- Faculty of Mathematics, Physics and Informatics, Comenius University in Bratislava, 842 48 Bratislava, Slovakia
- Institute of Experimental and Applied Physics, Czech Technical University in Prague, 128 00 Prague, Czech Republic
| | - V Singh
- University of California, Berkeley, California 94720, USA
| | - C Tomei
- INFN, Sezione di Roma, P.le Aldo Moro 2, I-00185 Rome, Italy
| | - V I Tretyak
- INFN, Laboratori Nazionali del Gran Sasso, I-67100 Assergi (AQ), Italy
- Institute for Nuclear Research of NASU, 03028 Kyiv, Ukraine
| | - V I Umatov
- National Research Centre Kurchatov Institute, Institute of Theoretical and Experimental Physics, 117218 Moscow, Russia
| | - L Vagneron
- Univ Lyon, Université Lyon 1, CNRS/IN2P3, IP2I-Lyon, F-69622 Villeurbanne, France
| | - M Velázquez
- Université Grenoble Alpes, CNRS, Grenoble INP, SIMAP, 38420 Saint Martin d'Hères, France
| | - B Ware
- John de Laeter Centre for Isotope Research, GPO Box U 1987, Curtin University, Bentley, Western Australia, Australia
| | - B Welliver
- University of California, Berkeley, California 94720, USA
| | - L Winslow
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - M Xue
- Department of Modern Physics, University of Science and Technology of China, Hefei 230027, People's Republic of China
| | - E Yakushev
- Laboratory of Nuclear Problems, JINR, 141980 Dubna, Moscow region, Russia
| | - M Zarytskyy
- Institute for Nuclear Research of NASU, 03028 Kyiv, Ukraine
| | - A S Zolotarova
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| |
Collapse
|
15
|
Carbonel H, Mikulski TD, Nugraha K, Johnston J, Wang Y, Brown SN. Optically active bis(aminophenols) and their metal complexes. Dalton Trans 2023; 52:13290-13303. [PMID: 37668189 DOI: 10.1039/d3dt02436a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/06/2023]
Abstract
Optically active C2-symmetric bis(aminophenols) based on (R)-2,2'-diaminobinaphthyl (BiniqH4) and (R,R)-2,3-butanediyldianthranilate (BdanH4) have been prepared by condensation of the diamines with 3,5-di-tert-butylcatechol. Group 10 bis(iminosemiquinone) complexes (R)-(Biniq)M (M = Pd, Pt) and (C,R,R)-(Bdan)Pd have been prepared by oxidatively metalating the corresponding ligands. In (R)-(Biniq)M, the C2 axis passes through the approximate square plane of the bis(iminosemiquinone)metal core, while in (C,R,R)-(Bdan)Pd the C2 axis is perpendicular to this plane. In the latter compound, the (R,R)-butanediyl strap binds selectively over one enantioface of the metal complex in a conformation where the methyl groups are anti to one another. Osmium oxo complexes with the intrinsically chiral OsO(amidophenoxide)2 chromophore are obtained by metalation of OsO(OCH2CH2O)2 with (R,R)-BdanH4. Both the (A,R,R) and (C,R,R) diastereomers can be observed, with metalation in refluxing toluene selectively giving the latter isomer. The electronic structures of the complexes are illuminated by the circular dichroism spectra, in conjuction with the optical spectra and TDDFT calculations.
Collapse
Affiliation(s)
- Halen Carbonel
- Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556-5670, USA.
| | - Timothy D Mikulski
- Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556-5670, USA.
| | - Kahargyan Nugraha
- Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556-5670, USA.
| | - James Johnston
- Department of Chemical and Biomolecular Engineering, University of Notre Dame, Notre Dame, IN 46556, USA
| | - Yichun Wang
- Department of Chemical and Biomolecular Engineering, University of Notre Dame, Notre Dame, IN 46556, USA
| | - Seth N Brown
- Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556-5670, USA.
| |
Collapse
|
16
|
Ashtari Esfahani A, Böser S, Buzinsky N, Carmona-Benitez MC, Claessens C, de Viveiros L, Doe PJ, Fertl M, Formaggio JA, Gaison JK, Gladstone L, Grando M, Guigue M, Hartse J, Heeger KM, Huyan X, Johnston J, Jones AM, Kazkaz K, LaRoque BH, Li M, Lindman A, Machado E, Marsteller A, Matthé C, Mohiuddin R, Monreal B, Mueller R, Nikkel JA, Novitski E, Oblath NS, Peña JI, Pettus W, Reimann R, Robertson RGH, Rosa De Jesús D, Rybka G, Saldaña L, Schram M, Slocum PL, Stachurska J, Sun YH, Surukuchi PT, Tedeschi JR, Telles AB, Thomas F, Thomas M, Thorne LA, Thümmler T, Tvrznikova L, Van De Pontseele W, VanDevender BA, Weintroub J, Weiss TE, Wendler T, Young A, Zayas E, Ziegler A. Tritium Beta Spectrum Measurement and Neutrino Mass Limit from Cyclotron Radiation Emission Spectroscopy. Phys Rev Lett 2023; 131:102502. [PMID: 37739382 DOI: 10.1103/physrevlett.131.102502] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/22/2023] [Revised: 06/26/2023] [Accepted: 07/17/2023] [Indexed: 09/24/2023]
Abstract
The absolute scale of the neutrino mass plays a critical role in physics at every scale, from the subatomic to the cosmological. Measurements of the tritium end-point spectrum have provided the most precise direct limit on the neutrino mass scale. In this Letter, we present advances by Project 8 to the cyclotron radiation emission spectroscopy (CRES) technique culminating in the first frequency-based neutrino mass limit. With only a cm^{3}-scale physical detection volume, a limit of m_{β}<155 eV/c^{2} (152 eV/c^{2}) is extracted from the background-free measurement of the continuous tritium beta spectrum in a Bayesian (frequentist) analysis. Using ^{83m}Kr calibration data, a resolution of 1.66±0.19 eV (FWHM) is measured, the detector response model is validated, and the efficiency is characterized over the multi-keV tritium analysis window. These measurements establish the potential of CRES for a high-sensitivity next-generation direct neutrino mass experiment featuring low background and high resolution.
Collapse
Affiliation(s)
- A Ashtari Esfahani
- Center for Experimental Nuclear Physics and Astrophysics and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - S Böser
- Institute for Physics, Johannes Gutenberg University Mainz, 55128 Mainz, Germany
| | - N Buzinsky
- Laboratory for Nuclear Science, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - M C Carmona-Benitez
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - C Claessens
- Center for Experimental Nuclear Physics and Astrophysics and Department of Physics, University of Washington, Seattle, Washington 98195, USA
- Institute for Physics, Johannes Gutenberg University Mainz, 55128 Mainz, Germany
| | - L de Viveiros
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - P J Doe
- Center for Experimental Nuclear Physics and Astrophysics and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - M Fertl
- Institute for Physics, Johannes Gutenberg University Mainz, 55128 Mainz, Germany
| | - J A Formaggio
- Laboratory for Nuclear Science, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - J K Gaison
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - L Gladstone
- Department of Physics, Case Western Reserve University, Cleveland, Ohio 44106, USA
| | - M Grando
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - M Guigue
- Laboratoire de Physique Nucléaire et de Hautes Énergies, Sorbonne Université, Université Paris Cité, CNRS/IN2P3, 75005 Paris, France
| | - J Hartse
- Center for Experimental Nuclear Physics and Astrophysics and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - K M Heeger
- Wright Laboratory and Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - X Huyan
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - J Johnston
- Laboratory for Nuclear Science, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - A M Jones
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - K Kazkaz
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - B H LaRoque
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - M Li
- Laboratory for Nuclear Science, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - A Lindman
- Institute for Physics, Johannes Gutenberg University Mainz, 55128 Mainz, Germany
| | - E Machado
- Center for Experimental Nuclear Physics and Astrophysics and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - A Marsteller
- Center for Experimental Nuclear Physics and Astrophysics and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - C Matthé
- Institute for Physics, Johannes Gutenberg University Mainz, 55128 Mainz, Germany
| | - R Mohiuddin
- Department of Physics, Case Western Reserve University, Cleveland, Ohio 44106, USA
| | - B Monreal
- Department of Physics, Case Western Reserve University, Cleveland, Ohio 44106, USA
| | - R Mueller
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - J A Nikkel
- Wright Laboratory and Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - E Novitski
- Center for Experimental Nuclear Physics and Astrophysics and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - N S Oblath
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - J I Peña
- Laboratory for Nuclear Science, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - W Pettus
- Center for Exploration of Energy and Matter and Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
| | - R Reimann
- Institute for Physics, Johannes Gutenberg University Mainz, 55128 Mainz, Germany
| | - R G H Robertson
- Center for Experimental Nuclear Physics and Astrophysics and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - D Rosa De Jesús
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - G Rybka
- Center for Experimental Nuclear Physics and Astrophysics and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - L Saldaña
- Wright Laboratory and Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - M Schram
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - P L Slocum
- Wright Laboratory and Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - J Stachurska
- Laboratory for Nuclear Science, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - Y-H Sun
- Department of Physics, Case Western Reserve University, Cleveland, Ohio 44106, USA
| | - P T Surukuchi
- Wright Laboratory and Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - J R Tedeschi
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - A B Telles
- Wright Laboratory and Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - F Thomas
- Institute for Physics, Johannes Gutenberg University Mainz, 55128 Mainz, Germany
| | - M Thomas
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - L A Thorne
- Institute for Physics, Johannes Gutenberg University Mainz, 55128 Mainz, Germany
| | - T Thümmler
- Institute of Astroparticle Physics, Karlsruhe Institute of Technology, 76021 Karlsruhe, Germany
| | - L Tvrznikova
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - W Van De Pontseele
- Laboratory for Nuclear Science, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - B A VanDevender
- Center for Experimental Nuclear Physics and Astrophysics and Department of Physics, University of Washington, Seattle, Washington 98195, USA
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - J Weintroub
- Center for Astrophysics, Harvard & Smithsonian, Cambridge, Massachusetts 02138, USA
| | - T E Weiss
- Wright Laboratory and Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - T Wendler
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - A Young
- Center for Astrophysics, Harvard & Smithsonian, Cambridge, Massachusetts 02138, USA
| | - E Zayas
- Laboratory for Nuclear Science, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - A Ziegler
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| |
Collapse
|
17
|
Byrne A, Allwood B, Schoeman I, Johnston J, Kalyatanda G, Makanda G, Mortimer K, Mitnick C, Nightingale R, Ozoh O, Rachow A, Van Der Zalm M. "Post tuberculosis": the urgent need for inclusion of lung health outcomes in tuberculosis treatment trials. Eur Respir J 2023; 62:2300950. [PMID: 37690787 PMCID: PMC10492662 DOI: 10.1183/13993003.00950-2023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2023] [Accepted: 07/03/2023] [Indexed: 09/12/2023]
Abstract
We read with interest the systematic review by Ivanova et al. [1], recently published in the European Respiratory Review , highlighting significant long-term lung function impairment experienced by people that survive tuberculosis (TB). Lung function impairment is a well-described characteristic of post-TB lung disease (PTLD), a condition that spans the spectrum of obstructive airway disease, bronchiectasis and fibro-cavitating disease, along with fungal and other respiratory infections [2]. The pathophysiology of PTLD will also be described in detail in the ERS Monograph entitled “The Challenge of Tuberculosis in the 21st Century”. New TB treatment regimens are a welcome advancement. However, for the millions of TB survivors with impaired lung function and quality of life, more holistic outcome measures and the inclusion of lung function is essential in future TB treatment trials. https://bit.ly/3PWT0o2
Collapse
Affiliation(s)
- Anthony Byrne
- St Vincent's Health Australia, Heart Lung Clinic, Sydney, Australia
- University of New South Wales, Sydney, Australia
| | - Brian Allwood
- University of Stellenbosch, Department of Medicine, Stellenbosch, South Africa
| | - Ingrid Schoeman
- TB Proof, Director of Advocacy and Strategy, Pretoria, South Africa
| | - James Johnston
- British Columbia Centre for Disease Control, Vancouver, BC, Canada
- University of British Columbia, Faculty of Medicine, Vancouver, BC, Canada
| | - Gautam Kalyatanda
- University of Florida, Department of Infectious Disease and Global Health, Gainesville, FL, USA
| | - Goodman Makanda
- South African Medical Research Council, Tygerberg, South Africa
| | - Kevin Mortimer
- Liverpool School of Tropical Medicine, Respiratory Medicine, Liverpool, UK
| | - Carole Mitnick
- Harvard University, Medical School and Department of Global Health and Social Medicine, Boston, MA, USA
| | | | - Obianuju Ozoh
- University of Lagos, Department of Medicine, Lagos, Nigeria
| | - Andrea Rachow
- LMU Munich, Division of Infectious Diseases and Tropical Medicine, Munich, Germany
| | - Marieke Van Der Zalm
- University of New South Wales, Sydney, Australia
- Desmond Tutu TB Centre, Paediatrics and Child Health, Cape Town, South Africa
| |
Collapse
|
18
|
Aldana PR, Hanel RA, Piatt J, Han SH, Bansal MM, Schultz C, Gauger C, Pederson JM, Iii JCW, Hulbert ML, Jordan LC, Qureshi A, Garrity K, Robert AP, Hatem A, Stein J, Beydler E, Adelson PD, Greene S, Grabb P, Johnston J, Lang SS, Leonard J, Magge SN, Scott A, Shah S, Smith ER, Smith J, Strahle J, Vadivelu S, Webb J, Wrubel D. Cerebral revascularization surgery reduces cerebrovascular events in children with sickle cell disease and moyamoya syndrome: Results of the stroke in sickle cell revascularization surgery retrospective study. Pediatr Blood Cancer 2023; 70:e30336. [PMID: 37057741 DOI: 10.1002/pbc.30336] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/09/2022] [Revised: 03/01/2023] [Accepted: 03/04/2023] [Indexed: 04/15/2023]
Abstract
BACKGROUND Recent studies suggest that cerebral revascularization surgery may be a safe and effective therapy to reduce stroke risk in patients with sickle cell disease and moyamoya syndrome (SCD-MMS). METHODS We performed a multicenter, retrospective study of children with SCD-MMS treated with conservative management alone (conservative group)-chronic blood transfusion and/or hydroxyurea-versus conservative management plus surgical revascularization (surgery group). We monitored cerebrovascular event (CVE) rates-a composite of strokes and transient ischemic attacks. Multivariable logistic regression was used to compare CVE occurrence and multivariable Poisson regression was used to compare incidence rates between groups. Covariates in multivariable models included age at treatment start, age at moyamoya diagnosis, antiplatelet use, CVE history, and the risk period length. RESULTS We identified 141 patients with SCD-MMS, 78 (55.3%) in the surgery group and 63 (44.7%) in the conservative group. Compared with the conservative group, preoperatively the surgery group had a younger age at moyamoya diagnosis, worse baseline modified Rankin scale scores, and increased prevalence of CVEs. Despite more severe pretreatment disease, the surgery group had reduced odds of new CVEs after surgery (odds ratio = 0.27, 95% confidence interval [CI] = 0.08-0.94, p = .040). Furthermore, comparing surgery group patients during presurgical versus postsurgical periods, CVEs odds were significantly reduced after surgery (odds ratio = 0.22, 95% CI = 0.08-0.58, p = .002). CONCLUSIONS When added to conservative management, cerebral revascularization surgery appears to reduce the risk of CVEs in patients with SCD-MMS. A prospective study will be needed to validate these findings.
Collapse
Affiliation(s)
- Philipp R Aldana
- Department of Neurosurgery, University of Florida College of Medicine - Jacksonville and Wolfson Children's Hospital, Jacksonville, Florida, USA
| | - Ricardo A Hanel
- Lyerly Neurosurgery, Baptist Neurological Institute, Jacksonville, Florida, USA
| | - Joseph Piatt
- Division of Neurosurgery, Nemours Neuroscience Center, A.I. duPont Hospital for Children, Wilmington, Delaware, USA
| | - Sabrina H Han
- University of Florida College of Medicine, Gainesville, Florida, USA
| | - Manisha M Bansal
- Department of Pediatric Hematology/Oncology, Nemours Children's Health System and Wolfson Children's Hospital, Jacksonville, Florida, USA
| | - Corinna Schultz
- Department of Pediatrics, Nemours Center for Cancer and Blood Disorders, Nemours Children's Hospital, Wilmington, Delaware, USA
| | - Cynthia Gauger
- Department of Pediatric Hematology/Oncology, Nemours Children's Health System and Wolfson Children's Hospital, Jacksonville, Florida, USA
| | - John M Pederson
- Superior Medical Experts, St. Paul, Minnesota, USA
- Nested Knowledge, St. Paul, Minnesota, USA
| | - John C Wellons Iii
- Division of Pediatric Neurological Surgery, Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Monica L Hulbert
- Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA
| | - Lori C Jordan
- Division of Pediatric Neurology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Adnan Qureshi
- Department of Neurology, Zeenat Qureshi Stroke Institute, University of Missouri, Columbia, Missouri, USA
| | - Kelsey Garrity
- Department of Neurosurgery, University of Florida College of Medicine - Jacksonville and Wolfson Children's Hospital, Jacksonville, Florida, USA
| | - Adam P Robert
- Department of Neurosurgery, University of Florida College of Medicine - Jacksonville and Wolfson Children's Hospital, Jacksonville, Florida, USA
| | - Asmaa Hatem
- Department of Neurosurgery, University of Florida College of Medicine - Jacksonville and Wolfson Children's Hospital, Jacksonville, Florida, USA
| | - Jennifer Stein
- University of Florida College of Medicine, Gainesville, Florida, USA
| | - Emily Beydler
- University of Florida College of Medicine, Gainesville, Florida, USA
| | - P David Adelson
- Barrow Neurological Institute, Phoenix Children's Hospital, Phoenix, Arizona, USA
| | - Stephanie Greene
- Department of Neurosurgery, Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Paul Grabb
- Department of Neurosurgery, Children's Mercy Hospital, Kansas, Missouri, USA
| | - James Johnston
- Department of Neurosurgery, Children's Hospital of Alabama, Birmingham, Alabama, USA
| | - Shih-Shan Lang
- Department of Neurosurgery and Pediatric Neurosurgery, University of Pennsylvania School of Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
| | - Jeffrey Leonard
- Department of Neurosurgery, Nationwide Children's Hospital, Columbus, Ohio, USA
| | - Suresh N Magge
- Department of Neurosurgery, CHOC Neuroscience Institute, Children's Health of Orange County, Orange, California, USA
| | - Alex Scott
- Department of Neurosurgery, Washington University School of Medicine, Washington University in Saint Louis, St Louis, Missouri, USA
| | - Sanjay Shah
- Department of Pediatric Hematology/Oncology, Phoenix Children's Hospital, Phoenix, Arizona, USA
| | - Edward R Smith
- Department of Neurosurgery, Children's Hospital Boston, and Harvard Medical School, Boston, Massachusetts, USA
| | - Jodi Smith
- Department of Pediatric Neurosurgery, Goodman Campbell Brain and Spine, Peyton Manning Children's Hospital, Indianapolis, Indiana, USA
| | - Jennifer Strahle
- Department of Neurosurgery, Washington University School of Medicine, Washington University in Saint Louis, St Louis, Missouri, USA
| | - Sudhakar Vadivelu
- Division of Neurosurgery, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
| | - Jennifer Webb
- Department of Hematology/Oncology, Children's National Hospital, Washington, District of Columbia, USA
| | - David Wrubel
- Department of Neurosurgery, Children's Healthcare of Atlanta, Egleston Hospital, Atlanta, Georgia, USA
| |
Collapse
|
19
|
Magel T, Meagher E, Boulter T, Albert A, Tsai M, Muñoz C, Carlsten C, Johnston J, Wong AW, Shah A, Ryerson C, Mckay RJ, Nacul L. Fatigue presentation, severity, and related outcomes in a prospective cohort following post-COVID-19 hospitalization in British Columbia, Canada. Front Med (Lausanne) 2023; 10:1179783. [PMID: 37457578 PMCID: PMC10344448 DOI: 10.3389/fmed.2023.1179783] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2023] [Accepted: 06/09/2023] [Indexed: 07/18/2023] Open
Abstract
Introduction Increasing evidence on long-term health outcomes following SARS CoV-2 infection shows post-viral symptoms can persist for months. These symptoms are often consistent with those of Myalgic Encephalomyelitis or Chronic Fatigue Syndrome (ME/CFS). The aim of the present study was to examine the prevalence and outcome predictors of post-viral fatigue and related symptoms 3- and 6-months following symptom onset. Methods A prospective cohort of patients hospitalized with Coronavirus disease (COVID-19) (n = 88) were recruited from a Post-COVID-19 Respiratory Clinic (PCRC) in Vancouver, Canada to examine predictors of long-term fatigue and substantial fatigue. Multivariable mixed effects analyses examined the relationship between patient predictors, including pre-existing comorbidities, patient reported outcome measures, and fatigue and substantial fatigue at follow-up. Results The number of patients experiencing fatigue or substantial fatigue at 3 months post-infection were 58 (67%) and 14 (16%) respectively. At 6 months these numbers declined to 47 (60%) patients experiencing fatigue and 6 (6%) experiencing substantial fatigue. Adjusted analysis, for sex, age, and time, revealed the number of pre-existing comorbidities to be associated with fatigue (OR 2.21; 95% CI 1.09-4.49; 0.028) and substantial fatigue (OR 1.73; 95% CI 1.06-2.95; 0.033) at 3 months follow-up. Except for shortness of breath, self-care, and follow-up time, all follow-up variables were found to be associated with fatigue and substantial fatigue at 3 months. Conclusion Fatigue and substantial fatigue are common after COVID-19 infection but often diminish over time. A significant number of patients continue to exhibit long-term fatigue at 6 months follow-up. Further research is needed to clarify the causality of viral infections in the development and severity of fatigue as a symptom and in meeting post-viral fatigue syndrome or ME/CFS diagnostic criteria.
Collapse
Affiliation(s)
- Tianna Magel
- Women’s Health Research Institute, British Columbia Women’s Hospital, Vancouver, BC, Canada
| | - Emily Meagher
- Women’s Health Research Institute, British Columbia Women’s Hospital, Vancouver, BC, Canada
| | - Travis Boulter
- Women’s Health Research Institute, British Columbia Women’s Hospital, Vancouver, BC, Canada
| | - Arianne Albert
- Women’s Health Research Institute, British Columbia Women’s Hospital, Vancouver, BC, Canada
| | - Melody Tsai
- Women’s Health Research Institute, British Columbia Women’s Hospital, Vancouver, BC, Canada
| | - Carola Muñoz
- Women’s Health Research Institute, British Columbia Women’s Hospital, Vancouver, BC, Canada
| | - Chris Carlsten
- Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
| | - James Johnston
- Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
| | - Alyson W. Wong
- Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
- Centre for Heart Lung Innovation, St. Paul’s Hospital, Vancouver, BC, Canada
| | - Aditi Shah
- Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
| | - Chris Ryerson
- Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
- Centre for Heart Lung Innovation, St. Paul’s Hospital, Vancouver, BC, Canada
| | - Rhonda Jane Mckay
- General Internal Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
| | - Luis Nacul
- Women’s Health Research Institute, British Columbia Women’s Hospital, Vancouver, BC, Canada
- Department of Family Practice, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
- CureME, London School of Hygiene and Tropical Medicine, London, United Kingdom
| |
Collapse
|
20
|
Johnston J, Stone T, Wang Y. Biomaterial-enabled 3D cell culture technologies for extracellular vesicle manufacturing. Biomater Sci 2023. [PMID: 37222265 DOI: 10.1039/d3bm00469d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
Extracellular vesicles (EVs) are lipid-based particles naturally released from cells and recognized as promising drug delivery vehicles for improving therapeutic outcomes. Efficient manufacturing of therapeutic EVs have been challenging for their clinical translations. Three-dimensional (3D) cell cultures enabled by biomaterial scaffolds have been used as a platform for improving EV manufacturing compared to conventional methods such as isolation from bodily fluids and standard Petri-dish cell culture. Recent studies on 3D culture derived EV production prove it to enhance the EV yield, functional cargos, and therapeutic efficacies. However, there are still challenges with scaling up 3D cell culture production platforms for industrial use. Hence, there is a high demand for designing, optimizing, and implementing large scale EV manufacturing platforms derived from 3D cell cultures. We will first review the current advances of biomaterial-enabled 3D cell cultures in EV manufacturing, followed by the effect of these 3D cell culture platforms on the EV yield, the EV quality, and therapeutic efficacies. Lastly, we will discuss the key challenges and potential for implementing biomaterial-enabled 3D culture in EV manufacturing for large scale processes in the industrial use.
Collapse
Affiliation(s)
- James Johnston
- Department of Chemical & Biomolecular Engineering, University of Notre Dame, 240C McCourtney Hall, Notre Dame, Indiana 46556, USA.
| | - Trevor Stone
- Department of Chemical & Biomolecular Engineering, University of Notre Dame, 240C McCourtney Hall, Notre Dame, Indiana 46556, USA.
| | - Yichun Wang
- Department of Chemical & Biomolecular Engineering, University of Notre Dame, 240C McCourtney Hall, Notre Dame, Indiana 46556, USA.
| |
Collapse
|
21
|
Taylor J, Bastos ML, Lachapelle-Chisholm S, Mayo NE, Johnston J, Menzies D. Residual respiratory disability after successful treatment of pulmonary tuberculosis: a systematic review and meta-analysis. EClinicalMedicine 2023; 59:101979. [PMID: 37205923 PMCID: PMC10189364 DOI: 10.1016/j.eclinm.2023.101979] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/02/2022] [Revised: 04/05/2023] [Accepted: 04/12/2023] [Indexed: 05/21/2023] Open
Abstract
Background Pulmonary tuberculosis (PTB) can result in long-term health consequences, even after successful treatment. We conducted a systematic review and meta-analysis to estimate the occurrence of respiratory impairment, other disability states, and respiratory complications following successful PTB treatment. Methods We identified studies from January 1, 1960, to December 6, 2022, describing populations of all ages that successfully completed treatment for active PTB and had been assessed for at least one of the following outcomes: occurrence of respiratory impairment, other disability states, or respiratory complications following PTB treatment. Studies were excluded if they reported on participants with self-reported TB, extra-pulmonary TB, inactive TB, latent TB, or if participants had been selected on the basis of having more advanced disease. Study characteristics and outcome-related data were abstracted. Meta-analysis was performed using a random effects model. We adapted the Newcastle Ottawa Scale to evaluate the methodological quality of the included studies. Heterogeneity was assessed using the I2 statistic and prediction intervals. Publication bias was assessed using Doi plots and LFK indices. This study is registered with PROSPERO (CRD42021276327). Findings 61 studies with 41,014 participants with PTB were included. In 42 studies reporting post-treatment lung function measurements, 59.1% (I2 = 98.3%) of participants with PTB had abnormal spirometry compared to 5.4% (I2 = 97.4%) of controls. Specifically, 17.8% (I2 = 96.6%) had obstruction, 21.3% (I2 = 95.4%) restriction, and 12.7% (I2 = 93.2%) a mixed pattern. Among 13 studies with 3179 participants with PTB, 72.6% (I2 = 92.8%) of participants with PTB had a Medical Research Council dyspnoea score of 1-2 and 24.7% (I2 = 92.2%) a score of 3-5. Mean 6-min walk distance in 13 studies was 440.5 m (I2 = 99.0%) in all participants (78.9% predicted, I2 = 98.9%) and 403.0 m (I2 = 95.1%) among MDR-TB participants in 3 studies (70.5% predicted, I2 = 97.6%). Four studies reported data on incidence of lung cancer, with an incidence rate ratio of 4.0 (95% CI 2.1-7.6) and incidence rate difference of 2.7 per 1000 person-years (95% CI 1.2-4.2) when compared to controls. Quality assessment indicated overall low-quality evidence in this field, heterogeneity was high for pooled estimates of nearly all outcomes of interest, and publication bias was considered likely for almost all outcomes. Interpretation The occurrence of post-PTB respiratory impairment, other disability states, and respiratory complications is high, adding to the potential benefits of disease prevention, and highlighting the need for optimised management after successful treatment. Funding Canadian Institutes of Health Research Foundation Grant.
Collapse
Affiliation(s)
- Joshua Taylor
- Respiratory Epidemiology and Clinical Research Unit, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
| | - Mayara Lisboa Bastos
- Respiratory Epidemiology and Clinical Research Unit, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
- Departments of Epidemiology, Biostatistics and Occupational Health, and Medicine, McGill University, Montreal, QC, Canada
| | - Sophie Lachapelle-Chisholm
- Respiratory Epidemiology and Clinical Research Unit, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
| | - Nancy E. Mayo
- Centre for Outcomes Research and Evaluation, McGill University, Montreal, QC, Canada
- School of Physical and Occupational Therapy, Faculty of Medicine, McGill University, Montreal, QC, Canada
| | - James Johnston
- Department of Medicine, University of British Columbia, Vancouver, BC, Canada
| | - Dick Menzies
- Respiratory Epidemiology and Clinical Research Unit, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
- Departments of Epidemiology, Biostatistics and Occupational Health, and Medicine, McGill University, Montreal, QC, Canada
- Centre for Outcomes Research and Evaluation, McGill University, Montreal, QC, Canada
- Corresponding author. 5252 de Maisonneuve West, Room 3D.58, McGill University, Montreal, QC H4A 3S5, Canada.
| |
Collapse
|
22
|
Nightingale R, Carlin F, Meghji J, McMullen K, Evans D, van der Zalm MM, Anthony MG, Bittencourt M, Byrne A, du Preez K, Coetzee M, Feris C, Goussard P, Hirasen K, Bouwer J, Hoddinott G, Huaman MA, Inglis-Jassiem G, Ivanova O, Karmadwala F, Schaaf HS, Schoeman I, Seddon JA, Sineke T, Solomons R, Thiart M, van Toorn R, Fujiwara PI, Romanowski K, Marais S, Hesseling AC, Johnston J, Allwood B, Muhwa JC, Mortimer K. Post-TB health and wellbeing. Int J Tuberc Lung Dis 2023; 27:248-283. [PMID: 37035971 PMCID: PMC10094053 DOI: 10.5588/ijtld.22.0514] [Citation(s) in RCA: 15] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2022] [Accepted: 11/02/2022] [Indexed: 04/11/2023] Open
Abstract
TB affects around 10.6 million people each year and there are now around 155 million TB survivors. TB and its treatments can lead to permanently impaired health and wellbeing. In 2019, representatives of TB affected communities attending the '1st International Post-Tuberculosis Symposium´ called for the development of clinical guidance on these issues. This clinical statement on post-TB health and wellbeing responds to this call and builds on the work of the symposium, which brought together TB survivors, healthcare professionals and researchers. Our document offers expert opinion and, where possible, evidence-based guidance to aid clinicians in the diagnosis and management of post-TB conditions and research in this field. It covers all aspects of post-TB, including economic, social and psychological wellbeing, post TB lung disease (PTLD), cardiovascular and pericardial disease, neurological disability, effects in adolescents and children, and future research needs.
Collapse
Affiliation(s)
- R Nightingale
- Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK, Department of Respiratory Medicine, Liverpool University Hospitals NHS foundation Trust, Liverpool, UK
| | - F Carlin
- Department of Infectious Diseases, Liverpool University Hospitals NHS foundation Trust, Liverpool, UK
| | - J Meghji
- Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK, Department of Respiratory Medicine, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK
| | - K McMullen
- Division of Neurology, Department of Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa
| | - D Evans
- Health Economics and Epidemiology Research Office, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - M M van der Zalm
- Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa
| | - M G Anthony
- Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa
| | - M Bittencourt
- University Hospital, University of Sao Paulo School of Medicine, Sao Paulo, SP, Brazil
| | - A Byrne
- Department of Thoracic Medicine, St Vincent´s Hospital Clinical School University of New South Wales, Sydney, NSW, Australia
| | - K du Preez
- Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa
| | - M Coetzee
- Division of Physiotherapy, Department of Health and Rehabilitation Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa
| | - C Feris
- Occupational Therapy Department, Windhoek Central Hospital, Ministry of Health and Social Services, Windhoek, Namibia, Division of Occupational Therapy, Department of Health and Rehabilitation Sciences, Stellenbosch University, Tygerberg, South Africa
| | - P Goussard
- Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa
| | - K Hirasen
- Health Economics and Epidemiology Research Office, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, Paediatric Pulmonology, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa
| | - J Bouwer
- Department of Psychiatry, University of the Witwatersrand, Johannesburg, South Africa
| | - G Hoddinott
- Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa
| | - M A Huaman
- University of Cincinnati College of Medicine, Cincinnati, OH, USA
| | - G Inglis-Jassiem
- Division of Physiotherapy, Department of Health and Rehabilitation Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa
| | - O Ivanova
- Division of Infectious Diseases and Tropical Medicine, Medical Centre of the University of Munich, German Centre for Infection Research, Partner Site Munich, Munich, Germany
| | - F Karmadwala
- Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK
| | - H S Schaaf
- Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa
| | | | - J A Seddon
- Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa, Department of Infectious Diseases, Imperial College London, London, UK
| | - T Sineke
- Health Economics and Epidemiology Research Office, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - R Solomons
- Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Tygerberg, South Africa
| | - M Thiart
- Division of Orthopaedic Surgery, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa
| | - R van Toorn
- Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Tygerberg, South Africa
| | - P I Fujiwara
- Task Force, Global Plan to End TB, 2023-2030, Stop TB Partnership, Geneva, Switzerland
| | - K Romanowski
- Department of Medicine, University of British Columbia, Vancouver, BC, Canada, Provincial TB Services, BC Centre for Disease Control, Vancouver, BC, Canada
| | - S Marais
- Division of Neurology, Department of Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa, Neurology Research Group, Neuroscience Institute, University of Cape Town, Cape Town, South Africa
| | - A C Hesseling
- Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa
| | - J Johnston
- Department of Medicine, University of British Columbia, Vancouver, BC, Canada, Provincial TB Services, BC Centre for Disease Control, Vancouver, BC, Canada
| | - B Allwood
- Division of Pulmonology, Department of Medicine, Faculty of Medicine, Health Sciences, Stellenbosch University, Cape Town, South Africa
| | - J C Muhwa
- Department of Medicine, Therapeutics, Dermatology and Psychiatry, Kenyatta University, Nairobi, Kenya
| | - K Mortimer
- Department of Respiratory Medicine, Liverpool University Hospitals NHS foundation Trust, Liverpool, UK, Department of Medicine, University of Cambridge, Cambridge, UK, Department of Paediatrics and Child Health, College of Health Sciences, School of Clinical Medicine, University of KwaZulu-Natal, Durban, South Africa
| |
Collapse
|
23
|
Cheung TT, Mai TH, Chia YL, Yap DYH, Lee CH, Chen CCK, Huang Y, Jin Y, Johnston J, Werkström V, Yao Y, Ge X, Zheng W. Safety, Tolerability, and Pharmacokinetics of Benralizumab: A Phase 1, Randomized, Single-Blind Study of Healthy Chinese Participants. Drug Des Devel Ther 2023; 17:209-218. [PMID: 36726737 PMCID: PMC9885872 DOI: 10.2147/dddt.s392155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2022] [Accepted: 12/27/2022] [Indexed: 01/26/2023] Open
Abstract
Purpose Biological therapies targeting eosinophils have been shown to be effective in treating patients with severe eosinophilic asthma. Benralizumab (Fasenra®, AstraZeneca) is a humanized monoclonal antibody binding to the alpha subunit of the interleukin-5 receptor, which rapidly depletes eosinophils via antibody-dependent cellular cytotoxicity. The aim of this Phase 1 study was to assess the safety, tolerability, and pharmacokinetics of benralizumab in healthy Chinese individuals. Materials and Methods In this randomized, single-blind study (NCT03928262), healthy Chinese adult participants aged 18 to 45 years, weighing 50 to 100 kg, were randomized 1:1:1 to receive a single subcutaneous (SC) injection of benralizumab 10 mg, 30 mg, or 100 mg in the upper arms on Day 1. Safety was monitored throughout the study (up to Day 85), and blood samples were taken to determine serum benralizumab concentrations and for detection of anti-drug antibody. A non-compartmental analysis was conducted to estimate the pharmacokinetic parameters. Results Thirty-six healthy participants were enrolled, 12 in each dose group (mean [SD] age 26 [6] years). Following a single SC injection of benralizumab, 13 adverse events were reported by 10 participants (28%), with one mild injection-site reaction assessed as related. The mean serum benralizumab concentrations increased in a dose proportional manner, followed by exponential decreases. The mean terminal half-lives were 15.1 days for the 10 mg dose, 14.4 days for the 30 mg dose, and 15.4 days for the 100 mg dose. All doses resulted in near-complete depletion of eosinophils on Day 2, which was maintained throughout the study to Day 85. Conclusion A single SC injection of benralizumab was well tolerated by healthy Chinese participants, with no new or unexpected safety findings. The pharmacokinetics of benralizumab in Chinese participants was dose-proportional and consistent with those of non-Chinese participants observed in previous studies. Clinical Trial Registration NCT03928262 (https://clinicaltrials.gov/ct2/show/NCT03928262).
Collapse
Affiliation(s)
- Tommy Tsang Cheung
- Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, People’s Republic of China
| | - Tu H Mai
- Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, South San Francisco, CA, USA
| | - Yen Lin Chia
- Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, South San Francisco, CA, USA,Correspondence: Yen Lin Chia, Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, 701 Gateway Blvd, South San Francisco, CA, 9408, USA, Tel +1 425 5272574, Email
| | - Desmond Y H Yap
- Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, People’s Republic of China
| | - Chi-Ho Lee
- Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, People’s Republic of China
| | - Cecil Chi-Keung Chen
- Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, South San Francisco, CA, USA
| | - Ying Huang
- Clinical Pharmacology, R&D China, AstraZeneca, Shanghai, People’s Republic of China
| | - Yuwen Jin
- Clinical Pharmacology, R&D China, AstraZeneca, Shanghai, People’s Republic of China
| | - James Johnston
- Late-stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
| | - Viktoria Werkström
- Late-Stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
| | - Yuhui Yao
- Respiratory & Immunology, R&D China, AstraZeneca, Shanghai, People’s Republic of China
| | - Xiaoyun Ge
- Clinical Safety, R&D China, AstraZeneca, Shanghai, People’s Republic of China
| | - Wenying Zheng
- Biometrics, R&D China, AstraZeneca, Shanghai, People’s Republic of China
| |
Collapse
|
24
|
Johnston J, Wagner Mackenzie B, Biswas K, Waldvogel-Thurlow S, Clark ST, Radcliff F, Mahadevan M, Douglas RG. The Effect of Amoxicillin with Clavulanate on the Microbiota of Tonsillar Tissue in Disease: a Randomized Control Trial. Microbiol Spectr 2022; 10:e0123922. [PMID: 36318025 PMCID: PMC9769914 DOI: 10.1128/spectrum.01239-22] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2022] [Accepted: 10/13/2022] [Indexed: 12/23/2022] Open
Abstract
Despite antibiotics being the primary medical treatment for recurrent tonsillitis, the impact of antibiotics on the tonsillar microbiome is not well understood. This study aimed to determine the effect of amoxicillin with clavulanate on the composition and quantity of bacteria in the tonsils of children with recurrent tonsillitis. A multicenter randomized clinical trial in Auckland, New Zealand was undertaken between August 1, 2017, and June 30, 2018. Sixty children undergoing tonsillectomy for the indication of recurrent tonsillitis were recruited for this study. Following random allocation, 30 participants were prescribed amoxicillin with clavulanate for the week before surgery. The remaining 30 received no antibiotics. Immediately following surgery, the crypts of the right and left tonsils were swabbed. Bacterial 16S rRNA gene-targeted amplicon sequencing and histological techniques were utilized. In the control group, there were significantly higher relative abundances of Haemophilus, Streptococcus, Neisseria, and Porphyromonas. Members from the genera Fusobacterium and Treponema were found to be significantly more abundant in the antibiotic group. There were no significant differences in the absolute quantities of bacteria between the groups. Microscopic examination found fewer bacterial microcolonies present in the tonsillar crypts of participants in the antibiotic group. Streptococcus pyogenes was not present in these bacterial microcolonies. These results suggest that a single course of antibiotics has a significant impact on the tonsil microbiota composition. The duration of this effect and the effect that the altered microbiome has on the course of the condition need to be determined. IMPORTANCE Several studies have identified the presence of multiple pathogenic bacteria in hyperplastic adenoids and palatine tonsils. However, there are currently no studies that utilize this technology to investigate the effect of oral antibiotics in children with recurrent tonsillitis on the tonsillar microbiome. This is the first study to investigate the effect of antibiotics on the microbiome of tonsillar tissue in children with recurrent tonsillitis using molecular techniques. This study has shown that participants who received amoxicillin with clavulanate immediately before tonsillectomy had a significantly reduced number of bacterial taxa commonly associated with recurrent tonsillitis, as well as the number of bacterial microcolonies observed in the tonsillar crypts. This novel finding suggests that either the effect of antibiotics is not sustained or that they are not an effective treatment for recurrent tonsillitis.
Collapse
Affiliation(s)
- James Johnston
- Department of Surgery, University of Auckland, Auckland, New Zealand
| | | | - Kristi Biswas
- Department of Surgery, University of Auckland, Auckland, New Zealand
| | | | - Sita Tarini Clark
- Department of Surgery, University of Auckland, Auckland, New Zealand
| | - Fiona Radcliff
- Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand
| | - Murali Mahadevan
- Department of Surgery, University of Auckland, Auckland, New Zealand
| | | |
Collapse
|
25
|
Adams DQ, Alduino C, Alfonso K, Avignone FT, Azzolini O, Bari G, Bellini F, Benato G, Beretta M, Biassoni M, Branca A, Brofferio C, Bucci C, Camilleri J, Caminata A, Campani A, Canonica L, Cao XG, Capelli S, Capelli C, Cappelli L, Cardani L, Carniti P, Casali N, Celi E, Chiesa D, Clemenza M, Copello S, Cremonesi O, Creswick RJ, D'Addabbo A, Dafinei I, Del Corso F, Dell'Oro S, Di Domizio S, Di Lorenzo S, Dompè V, Fang DQ, Fantini G, Faverzani M, Ferri E, Ferroni F, Fiorini E, Franceschi MA, Freedman SJ, Fu SH, Fujikawa BK, Ghislandi S, Giachero A, Gianvecchio A, Gironi L, Giuliani A, Gorla P, Gotti C, Gutierrez TD, Han K, Hansen EV, Heeger KM, Huang RG, Huang HZ, Johnston J, Keppel G, Kolomensky YG, Kowalski R, Liu R, Ma L, Ma YG, Marini L, Maruyama RH, Mayer D, Mei Y, Morganti S, Napolitano T, Nastasi M, Nikkel J, Nones C, Norman EB, Nucciotti A, Nutini I, O'Donnell T, Olmi M, Ouellet JL, Pagan S, Pagliarone CE, Pagnanini L, Pallavicini M, Pattavina L, Pavan M, Pessina G, Pettinacci V, Pira C, Pirro S, Pozzi S, Previtali E, Puiu A, Quitadamo S, Ressa A, Rosenfeld C, Sangiorgio S, Schmidt B, Scielzo ND, Sharma V, Singh V, Sisti M, Speller D, Surukuchi PT, Taffarello L, Terranova F, Tomei C, Vetter KJ, Vignati M, Wagaarachchi SL, Wang BS, Welliver B, Wilson J, Wilson K, Winslow LA, Zimmermann S, Zucchelli S. New Direct Limit on Neutrinoless Double Beta Decay Half-Life of ^{128}Te with CUORE. Phys Rev Lett 2022; 129:222501. [PMID: 36493444 DOI: 10.1103/physrevlett.129.222501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/06/2022] [Revised: 07/22/2022] [Accepted: 10/03/2022] [Indexed: 06/17/2023]
Abstract
The Cryogenic Underground Observatory for Rare Events (CUORE) at Laboratori Nazionali del Gran Sasso of INFN in Italy is an experiment searching for neutrinoless double beta (0νββ) decay. Its main goal is to investigate this decay in ^{130}Te, but its ton-scale mass and low background make CUORE sensitive to other rare processes as well. In this Letter, we present our first results on the search for 0νββ decay of ^{128}Te, the Te isotope with the second highest natural isotopic abundance. We find no evidence for this decay, and using a Bayesian analysis we set a lower limit on the ^{128}Te 0νββ decay half-life of T_{1/2}>3.6×10^{24} yr (90% CI). This represents the most stringent limit on the half-life of this isotope, improving by over a factor of 30 the previous direct search results, and exceeding those from geochemical experiments for the first time.
Collapse
Affiliation(s)
- D Q Adams
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - C Alduino
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - K Alfonso
- Department of Physics and Astronomy, University of California, Los Angeles, California 90095, USA
| | - F T Avignone
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - O Azzolini
- INFN-Laboratori Nazionali di Legnaro, Legnaro (Padova) I-35020, Italy
| | - G Bari
- INFN-Sezione di Bologna, Bologna I-40127, Italy
| | - F Bellini
- Dipartimento di Fisica, Sapienza Università di Roma, Roma I-00185, Italy
- INFN-Sezione di Roma, Roma I-00185, Italy
| | - G Benato
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
| | - M Beretta
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - M Biassoni
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
| | - A Branca
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - C Brofferio
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - C Bucci
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
| | - J Camilleri
- Center for Neutrino Physics, Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061, USA
| | - A Caminata
- INFN-Sezione di Genova, Genova I-16146, Italy
| | - A Campani
- INFN-Sezione di Genova, Genova I-16146, Italy
- Dipartimento di Fisica, Università di Genova, Genova I-16146, Italy
| | - L Canonica
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - X G Cao
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE), Institute of Modern Physics, Fudan University, Shanghai 200433, China
| | - S Capelli
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - C Capelli
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - L Cappelli
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
| | - L Cardani
- INFN-Sezione di Roma, Roma I-00185, Italy
| | - P Carniti
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - N Casali
- INFN-Sezione di Roma, Roma I-00185, Italy
| | - E Celi
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
- Gran Sasso Science Institute, L'Aquila I-67100, Italy
| | - D Chiesa
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - M Clemenza
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - S Copello
- INFN-Sezione di Genova, Genova I-16146, Italy
- Dipartimento di Fisica, Università di Genova, Genova I-16146, Italy
| | - O Cremonesi
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
| | - R J Creswick
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - A D'Addabbo
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
| | - I Dafinei
- INFN-Sezione di Roma, Roma I-00185, Italy
| | - F Del Corso
- INFN-Sezione di Bologna, Bologna I-40127, Italy
| | - S Dell'Oro
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - S Di Domizio
- INFN-Sezione di Genova, Genova I-16146, Italy
- Dipartimento di Fisica, Università di Genova, Genova I-16146, Italy
| | - S Di Lorenzo
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
| | - V Dompè
- Dipartimento di Fisica, Sapienza Università di Roma, Roma I-00185, Italy
- INFN-Sezione di Roma, Roma I-00185, Italy
| | - D Q Fang
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE), Institute of Modern Physics, Fudan University, Shanghai 200433, China
| | - G Fantini
- Dipartimento di Fisica, Sapienza Università di Roma, Roma I-00185, Italy
- INFN-Sezione di Roma, Roma I-00185, Italy
| | - M Faverzani
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - E Ferri
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
| | - F Ferroni
- INFN-Sezione di Roma, Roma I-00185, Italy
- Gran Sasso Science Institute, L'Aquila I-67100, Italy
| | - E Fiorini
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - M A Franceschi
- INFN-Laboratori Nazionali di Frascati, Frascati (Roma) I-00044, Italy
| | - S J Freedman
- Department of Physics, University of California, Berkeley, California 94720, USA
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - S H Fu
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE), Institute of Modern Physics, Fudan University, Shanghai 200433, China
| | - B K Fujikawa
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - S Ghislandi
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
- Gran Sasso Science Institute, L'Aquila I-67100, Italy
| | - A Giachero
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - A Gianvecchio
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - L Gironi
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - A Giuliani
- Universit Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - P Gorla
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
| | - C Gotti
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
| | - T D Gutierrez
- Physics Department, California Polytechnic State University, San Luis Obispo, California 93407, USA
| | - K Han
- INPAC and School of Physics and Astronomy, Shanghai Jiao Tong University; Shanghai Laboratory for Particle Physics and Cosmology, Shanghai 200240, China
| | - E V Hansen
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - K M Heeger
- Wright Laboratory, Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - R G Huang
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - H Z Huang
- Department of Physics and Astronomy, University of California, Los Angeles, California 90095, USA
| | - J Johnston
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - G Keppel
- INFN-Laboratori Nazionali di Legnaro, Legnaro (Padova) I-35020, Italy
| | - Yu G Kolomensky
- Department of Physics, University of California, Berkeley, California 94720, USA
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - R Kowalski
- Department of Physics and Astronomy, The Johns Hopkins University, 3400 North Charles Street Baltimore, Maryland 21211, USA
| | - R Liu
- Wright Laboratory, Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - L Ma
- Department of Physics and Astronomy, University of California, Los Angeles, California 90095, USA
| | - Y G Ma
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE), Institute of Modern Physics, Fudan University, Shanghai 200433, China
| | - L Marini
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
- Gran Sasso Science Institute, L'Aquila I-67100, Italy
| | - R H Maruyama
- Wright Laboratory, Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - D Mayer
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - Y Mei
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - S Morganti
- INFN-Sezione di Roma, Roma I-00185, Italy
| | - T Napolitano
- INFN-Laboratori Nazionali di Frascati, Frascati (Roma) I-00044, Italy
| | - M Nastasi
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - J Nikkel
- Wright Laboratory, Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - C Nones
- IRFU, CEA, Universit Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - E B Norman
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
- Department of Nuclear Engineering, University of California, Berkeley, California 94720, USA
| | - A Nucciotti
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - I Nutini
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - T O'Donnell
- Center for Neutrino Physics, Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061, USA
| | - M Olmi
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
| | - J L Ouellet
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - S Pagan
- Wright Laboratory, Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - C E Pagliarone
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
- Dipartimento di Ingegneria Civile e Meccanica, Università degli Studi di Cassino e del Lazio Meridionale, Cassino I-03043, Italy
| | - L Pagnanini
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
| | - M Pallavicini
- INFN-Sezione di Genova, Genova I-16146, Italy
- Dipartimento di Fisica, Università di Genova, Genova I-16146, Italy
| | - L Pattavina
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
| | - M Pavan
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - G Pessina
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
| | | | - C Pira
- INFN-Laboratori Nazionali di Legnaro, Legnaro (Padova) I-35020, Italy
| | - S Pirro
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
| | - S Pozzi
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - E Previtali
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - A Puiu
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
- Gran Sasso Science Institute, L'Aquila I-67100, Italy
| | - S Quitadamo
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
- Gran Sasso Science Institute, L'Aquila I-67100, Italy
| | - A Ressa
- Dipartimento di Fisica, Sapienza Università di Roma, Roma I-00185, Italy
- INFN-Sezione di Roma, Roma I-00185, Italy
| | - C Rosenfeld
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - S Sangiorgio
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - B Schmidt
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - N D Scielzo
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - V Sharma
- Center for Neutrino Physics, Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061, USA
| | - V Singh
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - M Sisti
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
| | - D Speller
- Department of Physics and Astronomy, The Johns Hopkins University, 3400 North Charles Street Baltimore, Maryland 21211, USA
| | - P T Surukuchi
- Wright Laboratory, Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | | | - F Terranova
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - C Tomei
- INFN-Sezione di Roma, Roma I-00185, Italy
| | - K J Vetter
- Department of Physics, University of California, Berkeley, California 94720, USA
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - M Vignati
- Dipartimento di Fisica, Sapienza Università di Roma, Roma I-00185, Italy
- INFN-Sezione di Roma, Roma I-00185, Italy
| | - S L Wagaarachchi
- Department of Physics, University of California, Berkeley, California 94720, USA
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - B S Wang
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
- Department of Nuclear Engineering, University of California, Berkeley, California 94720, USA
| | - B Welliver
- Department of Physics, University of California, Berkeley, California 94720, USA
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - J Wilson
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - K Wilson
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - L A Winslow
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - S Zimmermann
- Engineering Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - S Zucchelli
- INFN-Sezione di Bologna, Bologna I-40127, Italy
- Dipartimento di Fisica e Astronomia, Alma Mater Studiorum-Università di Bologna, Bologna I-40127, Italy
| |
Collapse
|
26
|
Wang S, Perlmutter JW, Johnston J, Nugent Z, Wiseman M. Rituximab Treatment of Primary Cutaneous Follicle Center Lymphoma: A Retrospective Review. J Cutan Med Surg 2022; 26:604-612. [PMID: 36134749 DOI: 10.1177/12034754221126119] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Primary cutaneous B-cell lymphoma (PCBCL) presents only in the skin at the time of diagnosis with no evidence of extracutaneous disease, and primary cutaneous follicle center lymphoma (PCFCL) is the most common subtype. There is currently a lack of prospective randomized control trials and large retrospective studies investigating the efficacy of different treatment options for PCFCL. This retrospective study was conducted to describe our local clinical experience and outcomes of patients treated with rituximab-containing regimens. OBJECTIVES To describe our local clinical experience and treatment outcomes of patients treated with rituximab-containing regimens. METHODS A retrospective study consisting of 25 PCFCL patients treated with different modalities. Patient records were reviewed and analyzed using a Kaplan-Meier estimation and SAS 9.4 software. RESULTS After the initial treatment, all patients had CR except for 1 patient in the observation group. Further, 60% of patients in surgery, 20% in chemoimmunotherapy, 67% in rituximab monotherapy, 33% in steroid injection/systemic prednisone, and 33% in observation experienced a relapse. Although no significant difference was found between treatment groups due to the small sample size, time to relapse trends provides insight into treatment responses. Chemoimmunotherapy had the lowest relapse rate in the first 5 years post-treatment, whereas surgery had a higher tendency to relapse. CONCLUSIONS Despite the potential for rituximab-containing chemoimmunotherapy to yield adverse effects, it is effective in achieving a prolonged clinical remission in patients with PCFCL. It remains a reasonable treatment option for diffuse, extensive, or treatment-resistant disease.
Collapse
Affiliation(s)
- Siru Wang
- 12359 University of Manitoba, Max Rady College of Medicine, Winnipeg, MB, Canada
| | - Jonah W Perlmutter
- 8665 Department of Biochemistry, University of Winnipeg, Winnipeg, MB, Canada
| | - James Johnston
- 8647 Department of Hematology and Oncology, CancerCare Manitoba, Winnipeg, MB, Canada
| | - Zoann Nugent
- 8647 Department of Epidemiology and Cancer Registry, CancerCare Manitoba, Winnipeg, MB, Canada
| | - Marni Wiseman
- 8664 Section of Dermatology, Department of Medicine, University of Manitoba, Winnipeg, MB, Canada.,SKiNWISE DERMATOLOGY, Winnipeg, Manitoba, Canada
| |
Collapse
|
27
|
Letessier TB, Johnston J, Delarue J, Martin B, Anderson RC. Spinner dolphin residency in tropical atoll lagoons: Diurnal presence, seasonal variability and implications for nutrient dynamics. J Zool (1987) 2022. [DOI: 10.1111/jzo.13000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- T. B. Letessier
- Institute of Zoology, Zoological Society of London Regent's Park London UK
- School of Biological Sciences University of Western Australia Perth SA Australia
| | - J. Johnston
- Institute of Zoology, Zoological Society of London Regent's Park London UK
- University College London London UK
| | - J. Delarue
- JASCO Applied Sciences The Roundel, St Clair's Farm Droxford UK
| | - B. Martin
- JASCO Applied Sciences The Roundel, St Clair's Farm Droxford UK
| | | |
Collapse
|
28
|
Velen K, Nguyen VN, Nguyen BH, Dang T, Nguyen HA, Vu DH, Do TT, Pham Duc C, Nguyen HL, Pham HT, Marais BJ, Johnston J, Britton W, Beardsley J, Negin J, Wiseman V, Marks GB, Nguyen TA, Fox GJ. Harnessing new mHealth technologies to Strengthen the Management of Multidrug-Resistant Tuberculosis in Vietnam (V-SMART trial): a protocol for a randomised controlled trial. BMJ Open 2022; 12:e052633. [PMID: 35732397 PMCID: PMC9226862 DOI: 10.1136/bmjopen-2021-052633] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
INTRODUCTION Multidrug-resistant tuberculosis (MDR-TB) remains a major public health problem globally. Long, complex treatment regimens coupled with frequent adverse events have resulted in poor treatment adherence and patient outcomes. Smartphone-based mobile health (mHealth) technologies offer national TB programmes an appealing platform to improve patient care and management; however, clinical trial evidence to support their use is lacking. This trial will test the hypothesis that an mHealth intervention can improve treatment success among patients with MDR-TB and is cost-effective compared with standard practice. METHODS AND ANALYSIS A community-based, open-label, parallel-group randomised controlled trial will be conducted among patients treated for MDR-TB in seven provinces of Vietnam. Patients commencing therapy for microbiologically confirmed rifampicin-resistant or multidrug-resistant tuberculosis within the past 30 days will be recruited to the study. Participants will be individually randomised to an intervention arm, comprising use of an mHealth application for treatment support, or a 'standard care' arm. In both arms, patients will be managed by the national TB programme according to current national treatment guidelines. The primary outcome measure of effectiveness will be the proportion of patients with treatment success (defined as treatment completion and/or bacteriological cure) after 24 months. A marginal Poisson regression model estimated via a generalised estimating equation will be used to test the effect of the intervention on treatment success. A prospective microcosting of the intervention and within-trial cost-effectiveness analysis will also be undertaken from a societal perspective. Cost-effectiveness will be presented as an incremental cost per patient successfully treated and an incremental cost per quality-adjusted life-year gained. ETHICS Ethical approval for the study was granted by The University of Sydney Human Research Ethics Committee (2019/676). DISSEMINATION Study findings will be disseminated to participants and published in peer-reviewed journals and conference proceedings. TRIAL REGISTRATION NUMBER ACTRN12620000681954.
Collapse
Affiliation(s)
- Kavindhran Velen
- Faculty of Health and Medicine, The University of Sydney, Sydney, New South Wales, Australia
| | | | | | - Tho Dang
- Woolcock Institute of Medical Research, Glebe, New South Wales, Australia
| | - Hoang Anh Nguyen
- National Drug Information and Adverse Drug Reaction Monitoring Centre, Hanoi, Vietnam
| | - Dinh Hoa Vu
- National Drug Information and Adverse Drug Reaction Monitoring Centre, Hanoi, Vietnam
| | | | - Cuong Pham Duc
- Woolcock Institute of Medical Research, Glebe, New South Wales, Australia
| | | | | | - Ben J Marais
- Faculty of Health and Medicine, The University of Sydney, Sydney, New South Wales, Australia
| | - James Johnston
- BCCDC, University of British Columbia Faculty of Medicine, Vancouver, British Columbia, Canada
| | - Warwick Britton
- Centenary Institute of Cancer Medicine and Cell Biology, The University of Sydney, Sydney, New South Wales, Australia
- Department of Clinical Immunology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
| | - Justin Beardsley
- Faculty of Health and Medicine, The University of Sydney, Sydney, New South Wales, Australia
| | - Joel Negin
- School of Public Health, The University of Sydney, Sydney, New South Wales, Australia
| | - Virginia Wiseman
- School of Public Health and Community Medicine, University of New South Wales, Sydney, New South Wales, Australia
- Health Economics, LSHTM, London, UK
| | | | | | - Greg J Fox
- Woolcock Institute of Medical Research, Glebe, New South Wales, Australia
- Central Clinical School, The University of Sydney Faculty of Medicine and Health, Sydney, New South Wales, Australia
| |
Collapse
|
29
|
Trudeau T, Prince E, Chatain O, Chee K, Jackson E, Limbrick D, Naftel R, Feldstein N, Grant G, Ginn K, Niazi T, Smith A, Kilburn L, Chern J, Drapeau A, Lam S, Johnston J, Dudley R, Staulcup S, Hankinson T. RARE-24. The use of novel in vitro models to study adamantinomatous craniopharyngioma disease biology and drug response. Neuro Oncol 2022. [PMCID: PMC9165211 DOI: 10.1093/neuonc/noac079.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
BACKGROUND: Challenges around the design and investigation of cell culture models of adamantinomatous craniopharyngioma (ACP) have arisen from the cellular heterogeneity of these tumors, with populations that harbor disparate requirements in culture. Novel approaches to in vitro modeling of ACP are needed. METHODS: Intraoperatively collected tumor specimens were mechanically digested and plated under conditions tailored to the cell population of interest. ACP tumor-derived fibroblasts and epithelial cells were isolated using serum-containing and keratinocyte-specific media respectively. ACP-derived epithelial cells were immortalized via SV40 virus transfection and puromycin treatment for stable cell-line generation. Cell line validation included immunofluorescence with markers appropriate for the cell population of interest. RNA sequencing of cell lines was compared to ACP transcriptome reference data. Cell typing was conducted using short tandem repeat sequencing. RESULTS: ACP fibroblasts and ACP epithelial cells maintained spindle-like and cobblestone morphologies respectively, even after 4 passages. Immunofluorescence staining confirmed high levels of Vimentin expression in ACP-derived fibroblasts, and panCK and B-catenin in ACP-derived epithelial cells. Point mutation in exon 3 of the CTNNB1 gene was identified in ACP-derived epithelial cells. CONCLUSION: Initial limits related to cell line development in ACP may be addressed through the isolation and culture-specific ACP cell populations. This experience demonstrates the maintenance of validated markers of the cell populations of interest ex vivo. While preliminary, such cell lines offer promise as tools for the identification and study of potential therapeutic vulnerabilities in ACP.
Collapse
Affiliation(s)
- Tammy Trudeau
- University of Colorado, School of Medicine , Aurora, CO , USA
| | - Eric Prince
- University of Colorado, School of Medicine , Aurora, CO , USA
| | - Oscar Chatain
- University of Colorado, School of Medicine , Aurora, CO , USA
| | - Keanu Chee
- University of Colorado, School of Medicine , Aurora, CO , USA
| | - Eric Jackson
- Johns Hopkins Medicine, Neurosurgery Department , Baltimore, MD , USA
| | - David Limbrick
- Washington University School of Medicine in St. Louis, St. Louis , MO , USA
| | - Robert Naftel
- Vanderbilt University Medical Center , Nashville, TN , USA
| | - Neil Feldstein
- Columbia University Irving Medical Center, New York , NY , USA
| | | | - Kevin Ginn
- Children's Mercy Kansas City, Kansas City , MO , USA
| | - Toba Niazi
- Nicklaus Children's Hospital , Miami, FL , USA
| | - Amy Smith
- Orlando Health Arnold Palmer Hospital for Children , Orlando, FL , USA
| | | | - Joshua Chern
- Children's Healthcare of Atlanta , Atlanta, GA , USA
| | | | - Sandi Lam
- Ann & Robert H. Lurie Hospital of Chicago , Chicago, IL , USA
| | | | - Roy Dudley
- Montreal Children's Hospital , Montreal , Canada
| | - Susan Staulcup
- University of Colorado, School of Medicine , Aurora, CO , USA
| | | |
Collapse
|
30
|
Chen R, Clark ST, Waldvogel-Thurlow S, Radcliff FJ, Hoggard ML, Johnston J, Douglas RG, Biswas K. The histological and microbiological characteristics of bacterial microcolonies in paediatric tonsillar hyperplasia. Int J Pediatr Otorhinolaryngol 2022; 157:111128. [PMID: 35421675 DOI: 10.1016/j.ijporl.2022.111128] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/16/2021] [Revised: 03/12/2022] [Accepted: 04/07/2022] [Indexed: 01/28/2023]
Abstract
INTRODUCTION Paediatric tonsillar hyperplasia (TH) is associated with a spectrum of presentations ranging from recurrent tonsillitis (RT) to sleep-disordered breathing (SDB). The underlying pathogenesis of tonsillar hyperplasia remains poorly understood. Previous studies have implicated bacterial microcolonies as targets of host inflammatory cells and as a potential driver of the chronic inflammation seen in TH. The role of atopy in tonsillar hyperplasia is also largely unknown. In this study, we aimed to determine the allergic responses and microbial factors that may influence TH in children. MATERIALS AND METHODS Paired tonsils and a serum sample were collected from 21 children undergoing tonsillectomy for RT or SDB in the Auckland region. The disposition of immunoglobulin isotypes (IgG, A, M and E) and local inflammatory cells on histological sections of tonsil tissue were determined using immunohistochemistry techniques. Aeroallergen specific IgE (sIgE) and Staphylococcal enterotoxin C specific IgE (SEC-specific IgE) were measured in serum and tonsil tissue using the ImmunoCAP® system. Finally, tonsil bacterial microcolonies were then excised from histological slides using laser microdissection techniques, before undergoing bacterial and fungal amplicon sequencing. RESULTS There were no significant differences in any of the measured variables between children with RT and SDB symptoms. IgE staining was not associated with increased levels of mast cells, leukocytes or plasma cells. However, sIgE positivity was more frequently found in local tissue than in serum (p = 0.025). A significant association was observed between tissue sIgE levels and tissue SEC-specific IgE levels (r2 = 0.95, p = 0.0001). The most abundant bacterial and fungal genera identified in the microcolonies were Fusobacterium, Sphingomonas, Porphyromonas, Prevotella and Malassezia. DISCUSSION These results suggest that there is a local IgE response in children with TH. Local IgE production is unrelated to systemic atopy and may play a key role in the pathogenesis of TH. This is the first study to determine the microbial composition of microcolonies in tonsil tissue. These findings enhance current understanding of the microbiology of tonsils in children with TH and have important implications for antibiotic strategies.
Collapse
Affiliation(s)
- Ruyan Chen
- Department of Surgery, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
| | - Sita Tarini Clark
- Department of Surgery, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
| | - Sharon Waldvogel-Thurlow
- Department of Surgery, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
| | - Fiona Jane Radcliff
- Department of Molecular Medicine and Pathology, The University of Auckland, Auckland, New Zealand
| | | | - James Johnston
- Department of Surgery, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
| | - Richard George Douglas
- Department of Surgery, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
| | - Kristi Biswas
- Department of Surgery, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.
| |
Collapse
|
31
|
Caruso G, Ciattaglia S, Colling B, Pace LD, Dongiovanni D, D'Onorio M, Garcia M, Jin X, Johnston J, Leichtle D, Pinna T, Porfiri M, Raskob W, Taylor N, Terranova N, Vale R. DEMO – The main achievements of the Pre – Concept phase of the safety and environmental work package and the development of the GSSR. Fusion Engineering and Design 2022. [DOI: 10.1016/j.fusengdes.2022.113025] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
32
|
Johnston J, O'Rourke C, Andrews R, Mills A. A silver-based ink for assessing low activity photocatalytic films. J Photochem Photobiol A Chem 2022. [DOI: 10.1016/j.jphotochem.2021.113698] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
33
|
Abstract
Dialysis adequacy for pediatric patients has largely followed the trends in adult dialysis by judging the success or adequacy of peritoneal or hemodialysis with urea kinetic modeling. While this provides a starting point to establish a dose of dialysis, it is clear that urea is only part of the picture. Many clinical parameters and interventions now have been identified that are just as impactful on mortality and morbidly as urea clearance. As such, our concept of adequacy is evolving to include non-urea parameters and assessing the impact that following an "adequate therapy" has on patient lives. As we move to a new era, we consider the impact these therapies have on patients and how it affects the quality of their lives; we must take these factors into consideration to achieve a therapy that is not just adequate, but livable.
Collapse
Affiliation(s)
- Linda Ding
- Department of Pediatrics and Child Health, University of Manitoba, Rady College of Medicine, Winnipeg, Manitoba, Canada
| | - James Johnston
- Department of Pediatrics and Child Health, University of Manitoba, Rady College of Medicine, Winnipeg, Manitoba, Canada
| | - Maury N Pinsk
- Department of Pediatrics and Child Health, University of Manitoba, Rady College of Medicine, Winnipeg, Manitoba, Canada.
| |
Collapse
|
34
|
Diver S, Khalfaoui L, Emson C, Wenzel SE, Menzies-Gow A, Wechsler ME, Johnston J, Molfino N, Parnes JR, Megally A, Colice G, Brightling CE. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med 2021; 9:1299-1312. [PMID: 34256031 DOI: 10.1016/s2213-2600(21)00226-5] [Citation(s) in RCA: 125] [Impact Index Per Article: 41.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Received: 03/29/2021] [Revised: 05/05/2021] [Accepted: 05/05/2021] [Indexed: 12/12/2022]
Abstract
BACKGROUND Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin (TSLP), an epithelial cell-derived cytokine. In phase 2b and 3 studies, tezepelumab significantly reduced exacerbations versus placebo in patients with severe uncontrolled asthma, irrespective of baseline levels of type 2 inflammatory biomarkers. We investigated the mechanism of action of tezepelumab by assessing its effects on airway inflammatory cells, airway remodelling, and airway hyperresponsiveness. METHODS CASCADE was an exploratory, double-blind, randomised, placebo-controlled, parallel-group, phase 2 study done in 27 medical centres in Canada, Denmark, Germany, the UK, and the USA. Adults aged 18-75 years with uncontrolled, moderate-to-severe asthma were randomly assigned (1:1) to receive tezepelumab 210 mg or placebo administered subcutaneously every 4 weeks for a planned 28 weeks, extended to up to 52 weeks if COVID-19-related disruption delayed participants' end-of-treatment assessments. Randomisation was balanced and stratified by blood eosinophil count. The primary endpoint was the change from baseline to the end of treatment in the number of airway submucosal inflammatory cells in bronchoscopic biopsy samples. Eosinophils, neutrophils, CD3+ T cells, CD4+ T cells, tryptase+ mast cells, and chymase+ mast cells were evaluated separately. This endpoint was also assessed in subgroups according to baseline type 2 inflammatory biomarker levels, including blood eosinophil count. Airway remodelling was assessed via the secondary endpoints of change from baseline in reticular basement membrane thickness and epithelial integrity (proportions of denuded, damaged, and intact epithelium). Exploratory outcomes included airway hyperresponsiveness to mannitol. All participants who completed at least 20 weeks of study treatment, had an end-of-treatment visit up to 8 weeks after the last dose of study drug, and had evaluable baseline and end-of-treatment bronchoscopies were included in the primary efficacy analysis. All participants who received at least one dose of study drug were included in the safety analyses. This study is registered with ClinicalTrials.gov, NCT03688074. FINDINGS Between Nov 2, 2018, and Nov 16, 2020, 250 patients were enrolled, 116 of whom were randomly assigned (59 to tezepelumab, 57 to placebo). 48 in the tezepelumab group and 51 in the placebo group completed the study and were assessed for the primary endpoint. Treatment with tezepelumab resulted in a nominally significantly greater reduction from baseline to the end of treatment in airway submucosal eosinophils versus placebo (ratio of geometric least-squares means 0·15 [95% CI 0·05-0·41]; nominal p<0·0010), with the difference seen across all baseline biomarker subgroups. There were no significant differences between treatment groups in the other cell types evaluated (ratio of geometric least-squares means: neutrophils 1·36 [95% CI 0·94-1·97]; CD3+ T cells 1·12 [0·86-1·46]; CD4+ T cells 1·18 [0·90-1·55]; tryptase+ mast cells 0·83 [0·61-1·15]; chymase+ mast cells 1·19 [0·67-2·10]; all p>0·10). In assessment of secondary endpoints, there were no significant differences between treatment groups in reticular basement membrane thickness and epithelial integrity. In an exploratory analysis, the reduction in airway hyperresponsiveness to mannitol was significantly greater with tezepelumab versus placebo (least-squares mean change from baseline in interpolated or extrapolated provoking dose of mannitol required to induce ≥15% reduction in FEV1 from baseline: tezepelumab 197·4 mg [95% CI 107·9 to 286·9]; placebo 58·6 mg [-30·1 to 147·33]; difference 138·8 [14·2 to 263·3], nominal p=0·030). Adverse events were reported in 53 (90%) patients in the tezepelumab group and 51 (90%) patients in the placebo group, and there were no safety findings of concern. INTERPRETATION The improvements in asthma clinical outcomes observed in previous studies with tezepelumab are probably driven, at least in part, by reductions in eosinophilic airway inflammation, as shown here by reduced airway eosinophil counts regardless of baseline blood eosinophil count. Tezepelumab also reduced airway hyperresponsiveness to mannitol, indicating that TSLP blockade might have additional benefits in asthma beyond reducing type 2 airway inflammation. FUNDING AstraZeneca and Amgen.
Collapse
Affiliation(s)
- Sarah Diver
- NIHR Leicester Biomedical Research Centre, Department of Respiratory Sciences, University of Leicester, Leicester, UK
| | - Latifa Khalfaoui
- NIHR Leicester Biomedical Research Centre, Department of Respiratory Sciences, University of Leicester, Leicester, UK
| | - Claire Emson
- Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA
| | - Sally E Wenzel
- University of Pittsburgh Asthma Institute, Pittsburgh, PA, USA
| | | | - Michael E Wechsler
- Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO, USA
| | - James Johnston
- Biometrics, Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
| | | | - Jane R Parnes
- Translational Medicine, Amgen, Thousand Oaks, CA, USA
| | - Ayman Megally
- Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA
| | - Gene Colice
- Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA
| | - Christopher E Brightling
- NIHR Leicester Biomedical Research Centre, Department of Respiratory Sciences, University of Leicester, Leicester, UK.
| |
Collapse
|
35
|
Armengaud E, Augier C, Barabash AS, Bellini F, Benato G, Benoît A, Beretta M, Bergé L, Billard J, Borovlev YA, Bourgeois C, Brudanin VB, Camus P, Cardani L, Casali N, Cazes A, Chapellier M, Charlieux F, Chiesa D, de Combarieu M, Dafinei I, Danevich FA, De Jesus M, Dixon T, Dumoulin L, Eitel K, Ferri F, Fujikawa BK, Gascon J, Gironi L, Giuliani A, Grigorieva VD, Gros M, Guerard E, Helis DL, Huang HZ, Huang R, Johnston J, Juillard A, Khalife H, Kleifges M, Kobychev VV, Kolomensky YG, Konovalov SI, Leder A, Loaiza P, Ma L, Makarov EP, de Marcillac P, Mariam R, Marini L, Marnieros S, Misiak D, Navick XF, Nones C, Norman EB, Novati V, Olivieri E, Ouellet JL, Pagnanini L, Pari P, Pattavina L, Paul B, Pavan M, Peng H, Pessina G, Pirro S, Poda DV, Polischuk OG, Pozzi S, Previtali E, Redon T, Rojas A, Rozov S, Rusconi C, Sanglard V, Scarpaci JA, Schäffner K, Schmidt B, Shen Y, Shlegel VN, Siebenborn B, Singh V, Tomei C, Tretyak VI, Umatov VI, Vagneron L, Velázquez M, Welliver B, Winslow L, Xue M, Yakushev E, Zarytskyy M, Zolotarova AS. New Limit for Neutrinoless Double-Beta Decay of ^{100}Mo from the CUPID-Mo Experiment. Phys Rev Lett 2021; 126:181802. [PMID: 34018798 DOI: 10.1103/physrevlett.126.181802] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/26/2020] [Revised: 02/02/2021] [Accepted: 04/05/2021] [Indexed: 06/12/2023]
Abstract
The CUPID-Mo experiment at the Laboratoire Souterrain de Modane (France) is a demonstrator for CUPID, the next-generation ton-scale bolometric 0νββ experiment. It consists of a 4.2 kg array of 20 enriched Li_{2}^{100}MoO_{4} scintillating bolometers to search for the lepton-number-violating process of 0νββ decay in ^{100}Mo. With more than one year of operation (^{100}Mo exposure of 1.17 kg×yr for physics data), no event in the region of interest and, hence, no evidence for 0νββ is observed. We report a new limit on the half-life of 0νββ decay in ^{100}Mo of T_{1/2}>1.5×10^{24} yr at 90% C.I. The limit corresponds to an effective Majorana neutrino mass ⟨m_{ββ}⟩<(0.31-0.54) eV, dependent on the nuclear matrix element in the light Majorana neutrino exchange interpretation.
Collapse
Affiliation(s)
- E Armengaud
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - C Augier
- Univ Lyon, Université Lyon 1, CNRS/IN2P3, IP2I-Lyon, F-69622 Villeurbanne, France
| | - A S Barabash
- National Research Centre Kurchatov Institute, Institute of Theoretical and Experimental Physics, 117218 Moscow, Russia
| | - F Bellini
- Dipartimento di Fisica, Sapienza Università di Roma, Piazzale Aldo Moro 2, I-00185 Rome, Italy
- INFN, Sezione di Roma, Piazzale Aldo Moro 2, I-00185 Rome, Italy
| | - G Benato
- INFN, Laboratori Nazionali del Gran Sasso, I-67100 Assergi (AQ), Italy
| | - A Benoît
- CNRS-Néel, 38042 Grenoble Cedex 9, France
| | - M Beretta
- University of California, Berkeley, California 94720, USA
| | - L Bergé
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - J Billard
- Univ Lyon, Université Lyon 1, CNRS/IN2P3, IP2I-Lyon, F-69622 Villeurbanne, France
| | - Yu A Borovlev
- Nikolaev Institute of Inorganic Chemistry, 630090 Novosibirsk, Russia
| | - Ch Bourgeois
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - V B Brudanin
- Laboratory of Nuclear Problems, JINR, 141980 Dubna, Moscow region, Russia
| | - P Camus
- CNRS-Néel, 38042 Grenoble Cedex 9, France
| | - L Cardani
- INFN, Sezione di Roma, Piazzale Aldo Moro 2, I-00185 Rome, Italy
| | - N Casali
- INFN, Sezione di Roma, Piazzale Aldo Moro 2, I-00185 Rome, Italy
| | - A Cazes
- Univ Lyon, Université Lyon 1, CNRS/IN2P3, IP2I-Lyon, F-69622 Villeurbanne, France
| | - M Chapellier
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - F Charlieux
- Univ Lyon, Université Lyon 1, CNRS/IN2P3, IP2I-Lyon, F-69622 Villeurbanne, France
| | - D Chiesa
- Dipartimento di Fisica, Università di Milano-Bicocca, I-20126 Milano, Italy
- INFN, Sezione di Milano-Bicocca, I-20126 Milano, Italy
| | - M de Combarieu
- IRAMIS, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - I Dafinei
- INFN, Sezione di Roma, Piazzale Aldo Moro 2, I-00185 Rome, Italy
| | - F A Danevich
- Institute for Nuclear Research of NASU, 03028 Kyiv, Ukraine
| | - M De Jesus
- Univ Lyon, Université Lyon 1, CNRS/IN2P3, IP2I-Lyon, F-69622 Villeurbanne, France
| | - T Dixon
- University of California, Berkeley, California 94720, USA
| | - L Dumoulin
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - K Eitel
- Karlsruhe Institute of Technology, Institute for Astroparticle Physics, 76021 Karlsruhe, Germany
| | - F Ferri
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - B K Fujikawa
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - J Gascon
- Univ Lyon, Université Lyon 1, CNRS/IN2P3, IP2I-Lyon, F-69622 Villeurbanne, France
| | - L Gironi
- Dipartimento di Fisica, Università di Milano-Bicocca, I-20126 Milano, Italy
- INFN, Sezione di Milano-Bicocca, I-20126 Milano, Italy
| | - A Giuliani
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - V D Grigorieva
- Nikolaev Institute of Inorganic Chemistry, 630090 Novosibirsk, Russia
| | - M Gros
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - E Guerard
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - D L Helis
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - H Z Huang
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE), Fudan University, Shanghai 200433, People's Republic of China
| | - R Huang
- University of California, Berkeley, California 94720, USA
| | - J Johnston
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - A Juillard
- Univ Lyon, Université Lyon 1, CNRS/IN2P3, IP2I-Lyon, F-69622 Villeurbanne, France
| | - H Khalife
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - M Kleifges
- Karlsruhe Institute of Technology, Institute for Data Processing and Electronics, 76021 Karlsruhe, Germany
| | - V V Kobychev
- Institute for Nuclear Research of NASU, 03028 Kyiv, Ukraine
| | - Yu G Kolomensky
- University of California, Berkeley, California 94720, USA
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - S I Konovalov
- National Research Centre Kurchatov Institute, Institute of Theoretical and Experimental Physics, 117218 Moscow, Russia
| | - A Leder
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - P Loaiza
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - L Ma
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE), Fudan University, Shanghai 200433, People's Republic of China
| | - E P Makarov
- Nikolaev Institute of Inorganic Chemistry, 630090 Novosibirsk, Russia
| | - P de Marcillac
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - R Mariam
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - L Marini
- INFN, Laboratori Nazionali del Gran Sasso, I-67100 Assergi (AQ), Italy
- University of California, Berkeley, California 94720, USA
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - S Marnieros
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - D Misiak
- Univ Lyon, Université Lyon 1, CNRS/IN2P3, IP2I-Lyon, F-69622 Villeurbanne, France
| | - X-F Navick
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - C Nones
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - E B Norman
- University of California, Berkeley, California 94720, USA
| | - V Novati
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - E Olivieri
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - J L Ouellet
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - L Pagnanini
- INFN, Laboratori Nazionali del Gran Sasso, I-67100 Assergi (AQ), Italy
- INFN, Gran Sasso Science Institute, I-67100 L'Aquila, Italy
| | - P Pari
- IRAMIS, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - L Pattavina
- INFN, Laboratori Nazionali del Gran Sasso, I-67100 Assergi (AQ), Italy
- Physik Department, Technische Universität München, Garching D-85748, Germany
| | - B Paul
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - M Pavan
- Dipartimento di Fisica, Università di Milano-Bicocca, I-20126 Milano, Italy
- INFN, Sezione di Milano-Bicocca, I-20126 Milano, Italy
| | - H Peng
- Department of Modern Physics, University of Science and Technology of China, Hefei 230027, People's Republic of China
| | - G Pessina
- INFN, Sezione di Milano-Bicocca, I-20126 Milano, Italy
| | - S Pirro
- INFN, Laboratori Nazionali del Gran Sasso, I-67100 Assergi (AQ), Italy
| | - D V Poda
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - O G Polischuk
- Institute for Nuclear Research of NASU, 03028 Kyiv, Ukraine
| | - S Pozzi
- INFN, Sezione di Milano-Bicocca, I-20126 Milano, Italy
| | - E Previtali
- Dipartimento di Fisica, Università di Milano-Bicocca, I-20126 Milano, Italy
- INFN, Sezione di Milano-Bicocca, I-20126 Milano, Italy
| | - Th Redon
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - A Rojas
- LSM, Laboratoire Souterrain de Modane, 73500 Modane, France
| | - S Rozov
- Laboratory of Nuclear Problems, JINR, 141980 Dubna, Moscow region, Russia
| | - C Rusconi
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - V Sanglard
- Univ Lyon, Université Lyon 1, CNRS/IN2P3, IP2I-Lyon, F-69622 Villeurbanne, France
| | - J A Scarpaci
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - K Schäffner
- INFN, Laboratori Nazionali del Gran Sasso, I-67100 Assergi (AQ), Italy
| | - B Schmidt
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - Y Shen
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE), Fudan University, Shanghai 200433, People's Republic of China
| | - V N Shlegel
- Nikolaev Institute of Inorganic Chemistry, 630090 Novosibirsk, Russia
| | - B Siebenborn
- Karlsruhe Institute of Technology, Institute for Astroparticle Physics, 76021 Karlsruhe, Germany
| | - V Singh
- University of California, Berkeley, California 94720, USA
| | - C Tomei
- INFN, Sezione di Roma, Piazzale Aldo Moro 2, I-00185 Rome, Italy
| | - V I Tretyak
- Institute for Nuclear Research of NASU, 03028 Kyiv, Ukraine
| | - V I Umatov
- National Research Centre Kurchatov Institute, Institute of Theoretical and Experimental Physics, 117218 Moscow, Russia
| | - L Vagneron
- Univ Lyon, Université Lyon 1, CNRS/IN2P3, IP2I-Lyon, F-69622 Villeurbanne, France
| | - M Velázquez
- Université Grenoble Alpes, CNRS, Grenoble INP, SIMAP, 38402 Saint Martin d'Héres, France
| | - B Welliver
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - L Winslow
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - M Xue
- Department of Modern Physics, University of Science and Technology of China, Hefei 230027, People's Republic of China
| | - E Yakushev
- Laboratory of Nuclear Problems, JINR, 141980 Dubna, Moscow region, Russia
| | - M Zarytskyy
- Institute for Nuclear Research of NASU, 03028 Kyiv, Ukraine
| | - A S Zolotarova
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| |
Collapse
|
36
|
Van Ankum E, Majcher K, Dolovich A, Johnston J, Boughner J. A Mouse Model Suggests How an Industrialized Diet Alters Jaw Form. FASEB J 2021. [DOI: 10.1096/fasebj.2021.35.s1.02209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Elsa Van Ankum
- Anatomy, Physiology, & PharmacologyUniversity of SaskatchewanSaskatoonSK
| | - Kadin Majcher
- Mechanical Engineering DepartmentUniversity of SaskatchewanSaskatoonSK
| | - Allan Dolovich
- Mechanical Engineering DepartmentUniversity of SaskatchewanSaskatoonSK
| | - James Johnston
- Mechanical Engineering DepartmentUniversity of SaskatchewanSaskatoonSK
| | - Julia Boughner
- Anatomy, Physiology, & PharmacologyUniversity of SaskatchewanSaskatoonSK
| |
Collapse
|
37
|
Adams DQ, Alduino C, Alfonso K, Avignone FT, Azzolini O, Bari G, Bellini F, Benato G, Biassoni M, Branca A, Brofferio C, Bucci C, Camilleri J, Caminata A, Campani A, Canonica L, Cao XG, Capelli S, Cappelli L, Cardani L, Carniti P, Casali N, Chiesa D, Clemenza M, Copello S, Cosmelli C, Cremonesi O, Creswick RJ, D'Addabbo A, Dafinei I, Davis CJ, Dell'Oro S, Di Domizio S, Dompè V, Fang DQ, Fantini G, Faverzani M, Ferri E, Ferroni F, Fiorini E, Franceschi MA, Freedman SJ, Fu SH, Fujikawa BK, Giachero A, Gironi L, Giuliani A, Gorla P, Gotti C, Gutierrez TD, Han K, Heeger KM, Huang RG, Huang HZ, Johnston J, Keppel G, Kolomensky YG, Ligi C, Ma L, Ma YG, Marini L, Maruyama RH, Mayer D, Mei Y, Moggi N, Morganti S, Napolitano T, Nastasi M, Nikkel J, Nones C, Norman EB, Nucciotti A, Nutini I, O'Donnell T, Ouellet JL, Pagan S, Pagliarone CE, Pagnanini L, Pallavicini M, Pattavina L, Pavan M, Pessina G, Pettinacci V, Pira C, Pirro S, Pozzi S, Previtali E, Puiu A, Rosenfeld C, Rusconi C, Sakai M, Sangiorgio S, Schmidt B, Scielzo ND, Sharma V, Singh V, Sisti M, Speller D, Surukuchi PT, Taffarello L, Terranova F, Tomei C, Vetter KJ, Vignati M, Wagaarachchi SL, Wang BS, Welliver B, Wilson J, Wilson K, Winslow LA, Zimmermann S, Zucchelli S. Measurement of the 2νββ Decay Half-Life of ^{130}Te with CUORE. Phys Rev Lett 2021; 126:171801. [PMID: 33988435 DOI: 10.1103/physrevlett.126.171801] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/23/2020] [Revised: 03/10/2021] [Accepted: 03/11/2021] [Indexed: 06/12/2023]
Abstract
We measured two-neutrino double beta decay of ^{130}Te using an exposure of 300.7 kg yr accumulated with the CUORE detector. Using a Bayesian analysis to fit simulated spectra to experimental data, it was possible to disentangle all the major background sources and precisely measure the two-neutrino contribution. The half-life is in agreement with past measurements with a strongly reduced uncertainty: T_{1/2}^{2ν}=7.71_{-0.06}^{+0.08}(stat)_{-0.15}^{+0.12}(syst)×10^{20} yr. This measurement is the most precise determination of the ^{130}Te 2νββ decay half-life to date.
Collapse
Affiliation(s)
- D Q Adams
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - C Alduino
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - K Alfonso
- Department of Physics and Astronomy, University of California, Los Angeles, California 90095, USA
| | - F T Avignone
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - O Azzolini
- INFN-Laboratori Nazionali di Legnaro, Legnaro (Padova) I-35020, Italy
| | - G Bari
- INFN-Sezione di Bologna, Bologna I-40127, Italy
| | - F Bellini
- Dipartimento di Fisica, Sapienza Università di Roma, Roma I-00185, Italy
- INFN-Sezione di Roma, Roma I-00185, Italy
| | - G Benato
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
| | - M Biassoni
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
| | - A Branca
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - C Brofferio
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - C Bucci
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
| | - J Camilleri
- Center for Neutrino Physics, Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061, USA
| | - A Caminata
- INFN-Sezione di Genova, Genova I-16146, Italy
| | - A Campani
- INFN-Sezione di Genova, Genova I-16146, Italy
- Dipartimento di Fisica, Università di Genova, Genova I-16146, Italy
| | - L Canonica
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - X G Cao
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE), Institute of Modern Physics, Fudan University, Shanghai 200433, China
| | - S Capelli
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - L Cappelli
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
- Department of Physics, University of California, Berkeley, California 94720, USA
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - L Cardani
- INFN-Sezione di Roma, Roma I-00185, Italy
| | - P Carniti
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - N Casali
- INFN-Sezione di Roma, Roma I-00185, Italy
| | - D Chiesa
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - M Clemenza
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - S Copello
- INFN-Sezione di Genova, Genova I-16146, Italy
- Dipartimento di Fisica, Università di Genova, Genova I-16146, Italy
| | - C Cosmelli
- Dipartimento di Fisica, Sapienza Università di Roma, Roma I-00185, Italy
- INFN-Sezione di Roma, Roma I-00185, Italy
| | - O Cremonesi
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
| | - R J Creswick
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - A D'Addabbo
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
- Gran Sasso Science Institute, L'Aquila I-67100, Italy
| | - I Dafinei
- INFN-Sezione di Roma, Roma I-00185, Italy
| | - C J Davis
- Wright Laboratory, Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - S Dell'Oro
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - S Di Domizio
- INFN-Sezione di Genova, Genova I-16146, Italy
- Dipartimento di Fisica, Università di Genova, Genova I-16146, Italy
| | - V Dompè
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
- Gran Sasso Science Institute, L'Aquila I-67100, Italy
| | - D Q Fang
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE), Institute of Modern Physics, Fudan University, Shanghai 200433, China
| | - G Fantini
- Dipartimento di Fisica, Sapienza Università di Roma, Roma I-00185, Italy
- INFN-Sezione di Roma, Roma I-00185, Italy
| | - M Faverzani
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - E Ferri
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - F Ferroni
- INFN-Sezione di Roma, Roma I-00185, Italy
- Gran Sasso Science Institute, L'Aquila I-67100, Italy
| | - E Fiorini
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - M A Franceschi
- INFN-Laboratori Nazionali di Frascati, Frascati (Roma) I-00044, Italy
| | - S J Freedman
- Department of Physics, University of California, Berkeley, California 94720, USA
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - S H Fu
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE), Institute of Modern Physics, Fudan University, Shanghai 200433, China
| | - B K Fujikawa
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - A Giachero
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - L Gironi
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - A Giuliani
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - P Gorla
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
| | - C Gotti
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
| | - T D Gutierrez
- Physics Department, California Polytechnic State University, San Luis Obispo, California 93407, USA
| | - K Han
- INPAC and School of Physics and Astronomy, Shanghai Jiao Tong University; Shanghai Laboratory for Particle Physics and Cosmology, Shanghai 200240, China
| | - K M Heeger
- Wright Laboratory, Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - R G Huang
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - H Z Huang
- Department of Physics and Astronomy, University of California, Los Angeles, California 90095, USA
| | - J Johnston
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - G Keppel
- INFN-Laboratori Nazionali di Legnaro, Legnaro (Padova) I-35020, Italy
| | - Yu G Kolomensky
- Department of Physics, University of California, Berkeley, California 94720, USA
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - C Ligi
- INFN-Laboratori Nazionali di Frascati, Frascati (Roma) I-00044, Italy
| | - L Ma
- Department of Physics and Astronomy, University of California, Los Angeles, California 90095, USA
| | - Y G Ma
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE), Institute of Modern Physics, Fudan University, Shanghai 200433, China
| | - L Marini
- Department of Physics, University of California, Berkeley, California 94720, USA
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - R H Maruyama
- Wright Laboratory, Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - D Mayer
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - Y Mei
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - N Moggi
- INFN-Sezione di Bologna, Bologna I-40127, Italy
- Dipartimento di Fisica e Astronomia, Alma Mater Studiorum-Università di Bologna, Bologna I-40127, Italy
| | - S Morganti
- INFN-Sezione di Roma, Roma I-00185, Italy
| | - T Napolitano
- INFN-Laboratori Nazionali di Frascati, Frascati (Roma) I-00044, Italy
| | - M Nastasi
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - J Nikkel
- Wright Laboratory, Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - C Nones
- IRFU, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France
| | - E B Norman
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
- Department of Nuclear Engineering, University of California, Berkeley, California 94720, USA
| | - A Nucciotti
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - I Nutini
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - T O'Donnell
- Center for Neutrino Physics, Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061, USA
| | - J L Ouellet
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - S Pagan
- Wright Laboratory, Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - C E Pagliarone
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
- Dipartimento di Ingegneria Civile e Meccanica, Università degli Studi di Cassino e del Lazio Meridionale, Cassino I-03043, Italy
| | - L Pagnanini
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
- Gran Sasso Science Institute, L'Aquila I-67100, Italy
| | - M Pallavicini
- INFN-Sezione di Genova, Genova I-16146, Italy
- Dipartimento di Fisica, Università di Genova, Genova I-16146, Italy
| | - L Pattavina
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
| | - M Pavan
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - G Pessina
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
| | | | - C Pira
- INFN-Laboratori Nazionali di Legnaro, Legnaro (Padova) I-35020, Italy
| | - S Pirro
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
| | - S Pozzi
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - E Previtali
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - A Puiu
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
- Gran Sasso Science Institute, L'Aquila I-67100, Italy
| | - C Rosenfeld
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - C Rusconi
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
| | - M Sakai
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - S Sangiorgio
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - B Schmidt
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - N D Scielzo
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - V Sharma
- Center for Neutrino Physics, Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061, USA
| | - V Singh
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - M Sisti
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
| | - D Speller
- Department of Physics and Astronomy, The Johns Hopkins University, 3400 North Charles Street Baltimore, Maryland 21211, USA
| | - P T Surukuchi
- Wright Laboratory, Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | | | - F Terranova
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - C Tomei
- INFN-Sezione di Roma, Roma I-00185, Italy
| | - K J Vetter
- Department of Physics, University of California, Berkeley, California 94720, USA
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - M Vignati
- INFN-Sezione di Roma, Roma I-00185, Italy
| | - S L Wagaarachchi
- Department of Physics, University of California, Berkeley, California 94720, USA
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - B S Wang
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
- Department of Nuclear Engineering, University of California, Berkeley, California 94720, USA
| | - B Welliver
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - J Wilson
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - K Wilson
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - L A Winslow
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - S Zimmermann
- Engineering Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - S Zucchelli
- INFN-Sezione di Bologna, Bologna I-40127, Italy
- Dipartimento di Fisica e Astronomia, Alma Mater Studiorum-Università di Bologna, Bologna I-40127, Italy
| |
Collapse
|
38
|
Oxlade O, Benedetti A, Adjobimey M, Alsdurf H, Anagonou S, Cook VJ, Fisher D, Fox GJ, Fregonese F, Hadisoemarto P, Hill PC, Johnston J, Khan FA, Long R, Nguyen NV, Nguyen TA, Obeng J, Ruslami R, Schwartzman K, Trajman A, Valiquette C, Menzies D. Effectiveness and cost-effectiveness of a health systems intervention for latent tuberculosis infection management (ACT4): a cluster-randomised trial. Lancet Public Health 2021; 6:e272-e282. [PMID: 33765453 DOI: 10.1016/s2468-2667(20)30261-9] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/25/2020] [Revised: 10/15/2020] [Accepted: 10/23/2020] [Indexed: 01/30/2023]
Abstract
BACKGROUND Reaching the UN General Assembly High-Level Meeting on Tuberculosis target of providing tuberculosis preventive treatment to at least 30 million people by 2022, including 4 million children under the age of 5 years and 20 million other household contacts, will require major efforts to strengthen health systems. The aim of this study was to evaluate the effectiveness and cost-effectiveness of a health systems intervention to strengthen management for latent tuberculosis infection (LTBI) in household contacts of confirmed tuberculosis cases. METHODS ACT4 was a cluster-randomised, open-label trial involving 24 health facilities in Benin, Canada, Ghana, Indonesia, and Vietnam randomly assigned to either a three-phase intervention (LTBI programme evaluation, local decision making, and strengthening activities) or control (standard LTBI care). Tuberculin and isoniazid were provided to control and intervention sites if not routinely available. Randomisation was stratified by country and restricted to ensure balance of index patients with tuberculosis by arm and country. The primary outcome was the number of household contacts who initiated tuberculosis preventive treatment at each health facility within 4 months of the diagnosis of the index case, recorded in the first or last 6 months of our 20-month study. To ease interpretation, this number was standardised per 100 newly diagnosed index patients with tuberculosis. Analysis was by intention to treat. Masking of staff at the coordinating centre and sites was not possible; however, those analysing data were masked to assignment of intervention or control. An economic analysis of the intervention was done in parallel with the trial. ACT4 is registered at ClinicalTrials.gov, NCT02810678. FINDINGS The study was done between Aug 1, 2016, and March 31, 2019. During the first 6 months of the study the crude overall proportion of household contacts initiating tuberculosis preventive treatment out of those eligible at intervention sites was 0·21. After the implementation of programme strengthening activities, the proportion initiating tuberculosis preventive treatment increased to 0·35. Overall, the number of household contacts initiating tuberculosis preventive treatment per 100 index patients with tuberculosis increased between study phases in intervention sites (adjusted rate difference 60, 95% CI 4 to 116), while control sites showed no statistically significant change (-12, -33 to 10). There was a difference in rate differences of 72 (95% CI 10 to 134) contacts per 100 index patients with tuberculosis initiating preventive treatment associated with the intervention. The total cost for the intervention, plus LTBI clinical care per additional contact initiating treatment was estimated to be CA$1348 (range 724 to 9708). INTERPRETATION A strategy of standardised evaluation, local decision making, and implementation of health systems strengthening activities can provide a mechanism for scale-up of tuberculosis prevention, particularly in low-income and middle-income countries. FUNDING Canadian Institutes of Health Research.
Collapse
Affiliation(s)
- Olivia Oxlade
- McGill International TB Centre, Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada
| | - Andrea Benedetti
- McGill International TB Centre, Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada
| | - Mênonli Adjobimey
- Centre National Hospitalier Universitaire de Pneumo-Pthisiologie de Cotonou, Cotonou, Benin
| | - Hannah Alsdurf
- McGill International TB Centre, Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada
| | | | - Victoria J Cook
- Provincial TB Services, BC Centre for Disease Control, Vancouver, BC, Canada; Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
| | | | - Greg J Fox
- The Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia
| | - Federica Fregonese
- McGill International TB Centre, Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada
| | - Panji Hadisoemarto
- TB-HIV Research Center, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia; Department of Public Health, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
| | - Philip C Hill
- Centre for International Health, Faculty of Medicine, University of Otago, Otago, New Zealand
| | - James Johnston
- Provincial TB Services, BC Centre for Disease Control, Vancouver, BC, Canada; Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
| | - Faiz Ahmad Khan
- McGill International TB Centre, Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada
| | - Richard Long
- Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
| | | | - Thu Anh Nguyen
- The Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; The Woolcock Institute of Medical Research in Vietnam, Hanoi, Vietnam
| | | | - Rovina Ruslami
- TB-HIV Research Center, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia; Department of Public Health, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
| | - Kevin Schwartzman
- McGill International TB Centre, Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada
| | - Anete Trajman
- McGill International TB Centre, Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada; Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
| | - Chantal Valiquette
- McGill International TB Centre, Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada
| | - Dick Menzies
- McGill International TB Centre, Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada.
| |
Collapse
|
39
|
Di Y, Wasan EK, Cawthray J, Syeda J, Ali M, Cooper DML, Al-Dissi A, Ashjaee N, Cheng W, Johnston J, Weekes DM, Kostelnik TI, Orvig C, Wasan KM. Evaluation of La(XT), a novel lanthanide compound, in an OVX rat model of osteoporosis. Bone Rep 2021; 14:100753. [PMID: 33665236 PMCID: PMC7905442 DOI: 10.1016/j.bonr.2021.100753] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/07/2020] [Revised: 12/24/2020] [Accepted: 02/03/2021] [Indexed: 11/16/2022] Open
Abstract
Purpose The purpose of this study was to evaluate the efficacy and toxicity of a novel lanthanum compound, La(XT), in an ovariectomized (OVX) rat model of osteoporosis. Methods Twenty-four ovariectomized female Sprague Dawley rats were divided into 3 groups receiving a research diet with/without treatment compounds (alendronate: 3 mg/kg; La(XT) 100 mg/kg) for three months. At the time of sacrifice, the kidney, liver, brain, lung and spleen were collected for histological examination. The trabecular bone structure of the tibiae was evaluated using micro-CT and a three-point metaphyseal mechanical test was used to evaluate bone failure load and stiffness. Results No significant differences were noted in plasma levels of calcium, phosphorus, creatinine, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) between the La(XT) treatment compared to the non-treated OVX group. Alendronate-treated animals (positive control) showed higher BV/TV, Tb.N and lower Tb.Th and Tb.Sp when compared to the non-treated OVX group. Mechanical analysis indicated that stiffness was higher in the alendronate (32.88%, p = 0.04) when compared to the non-treated OVX group. Failure load did not differ among the groups. Conclusions No kidney or liver toxicities of La(XT) treatments were found during the three-month study. The absence of liver and kidney toxicity with drug treatment for 3 months, as well as the increased trabecular bone stiffness are encouraging for the pursuit of further studies with La(XT) for a longer duration of time.
Collapse
Key Words
- ALT, alanine aminotransferase
- AST, aspartate aminotransferase
- BMD, bone mineral density
- BV/TV, bone volume fraction
- CRF, chronic renal failure
- Ca2+, calcium
- Cr, creatinine
- HAP, hydroxyapatite
- La(XT)
- La3+, lanthanum
- Lanthanum
- OVX
- OVX, ovariectomized
- Osteoporosis
- SD, Sprague Dawley
- Tb.N, trabecular number
- Tb.Sp, trabecular separation
- Tb.Th, trabecular thickness
- Toxicity
Collapse
Affiliation(s)
- Yunyun Di
- College of Pharmacy and Nutrition, University of Saskatchewan, 104 Clinic Place, Saskatoon, SK S7N 2Z4, Canada
| | - Ellen K Wasan
- College of Pharmacy and Nutrition, University of Saskatchewan, 104 Clinic Place, Saskatoon, SK S7N 2Z4, Canada
| | - Jacqueline Cawthray
- College of Pharmacy and Nutrition, University of Saskatchewan, 104 Clinic Place, Saskatoon, SK S7N 2Z4, Canada
| | - Jaweria Syeda
- College of Pharmacy and Nutrition, University of Saskatchewan, 104 Clinic Place, Saskatoon, SK S7N 2Z4, Canada
| | - Munawar Ali
- College of Pharmacy and Nutrition, University of Saskatchewan, 104 Clinic Place, Saskatoon, SK S7N 2Z4, Canada
| | - David M L Cooper
- Department of Anatomy Physiology and Pharmacology, College of Medicine, University of Saskatchewan, 107 Wiggins Road, Saskatoon, SK S7N 5E5, Canada
| | - Ahmad Al-Dissi
- Western College of Veterinary Medicine, University of Saskatchewan, 52 Campus Drive, Saskatoon, SK S7N 5B4, Canada
| | - Nima Ashjaee
- College of Engineering, University of Saskatchewan, 57 Campus Drive, Saskatoon, SK S7N 5A9, Canada
| | - Wubin Cheng
- College of Engineering, University of Saskatchewan, 57 Campus Drive, Saskatoon, SK S7N 5A9, Canada
| | - James Johnston
- College of Engineering, University of Saskatchewan, 57 Campus Drive, Saskatoon, SK S7N 5A9, Canada
| | - David M Weekes
- Medicinal Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, BC V6T 1Z1, Canada
| | - Thomas I Kostelnik
- Medicinal Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, BC V6T 1Z1, Canada
| | - Chris Orvig
- Medicinal Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, BC V6T 1Z1, Canada
| | - Kishor M Wasan
- College of Pharmacy and Nutrition, University of Saskatchewan, 104 Clinic Place, Saskatoon, SK S7N 2Z4, Canada.,Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| |
Collapse
|
40
|
Lux CA, Wagner Mackenzie B, Johnston J, Zoing M, Biswas K, Taylor MW, Douglas RG. Antibiotic Treatment for Chronic Rhinosinusitis: Prescription Patterns and Associations With Patient Outcome and the Sinus Microbiota. Front Microbiol 2020; 11:595555. [PMID: 33414772 PMCID: PMC7782326 DOI: 10.3389/fmicb.2020.595555] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2020] [Accepted: 11/26/2020] [Indexed: 12/13/2022] Open
Abstract
Background Chronic rhinosinusitis (CRS) is a common and debilitating inflammatory condition of the sinuses, afflicting 5% of the general population. Although antibiotics are frequently prescribed for the medical management of CRS, there is surprisingly little evidence to support their efficacy. In this study, we aimed to establish associations between medication usage, the sinus microbiota and patients’ clinical outcomes. Methods Antibiotic prescription patterns for the year before sample collection of 156 CRS patients, 45 disease control patients (mostly requiring septoplasty and inferior turbinate reduction) and 35 healthy control subjects were examined and analyzed together with previously published bacterial 16S rRNA gene amplicon data from our group. Results The highest antibiotic usage was observed among the two CRS patient categories. Despite heavy antibiotic usage, CRS patients’ clinical outcomes as indicated by patient questionnaires and radiologic scores were similar to those patients that did not receive any antibiotics. The sinus microbiota was dominated by members of the bacterial genera Corynebacterium and Staphylococcus in all three cohorts. Bacterial community dispersion as measured by principal coordinate analysis was significantly higher in CRS patients compared to healthy control subjects, but not disease control patients. Pairwise comparisons within cohorts revealed differences in the relative 16S rRNA gene sequence abundances of the genera Staphylococcus and Lawsonella between antibiotic users and non-users. However, overall antibiotic effects were minimal and unpredictable. Conclusion The unpredictable effects of antibiotic treatment on the sinus microbiota found in this study, together with the lack of differences in patients’ symptom scores between cohorts, do not support preoperative antibiotic treatment for CRS patients.
Collapse
Affiliation(s)
- Christian A Lux
- School of Biological Sciences, University of Auckland, Auckland, New Zealand.,Department of Surgery, School of Medicine, University of Auckland, Auckland, New Zealand
| | - Brett Wagner Mackenzie
- Department of Surgery, School of Medicine, University of Auckland, Auckland, New Zealand
| | - James Johnston
- Department of Surgery, School of Medicine, University of Auckland, Auckland, New Zealand
| | - Melissa Zoing
- Department of Surgery, School of Medicine, University of Auckland, Auckland, New Zealand
| | - Kristi Biswas
- Department of Surgery, School of Medicine, University of Auckland, Auckland, New Zealand
| | - Michael W Taylor
- School of Biological Sciences, University of Auckland, Auckland, New Zealand
| | - Richard G Douglas
- Department of Surgery, School of Medicine, University of Auckland, Auckland, New Zealand
| |
Collapse
|
41
|
Mirsky D, Prince E, Staulcup S, Hengartner A, Vijmasi T, Johnston J, Massimi L, Anderson R, Souweidane M, Naftel R, Limbrick D, Grant G, Niazi T, Dudley R, Kilburn L, Jackson E, Jallo G, Ginn K, Smith A, Chern J, Lee A, Drapeau A, Krieger M, Handler M, Hankinson T. RARE-11. QUANTITATIVE MR IMAGING FEATURES ASSOCIATED WITH UNIQUE TRANSCRIPTIONAL CHARACTERISTICS IN PEDIATRIC ADAMANTINOMATOUS CRANIOPHARYNGIOMA: A POTENTIAL GUIDE FOR THERAPY. Neuro Oncol 2020. [PMCID: PMC7715942 DOI: 10.1093/neuonc/noaa222.722] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
METHODS Through the Advancing Treatment for Pediatric Craniopharyngioma (ATPC) consortium we accumulated preoperative MRIs and tumor RNA for 50 unique ACP patients. MRIs were assessed quantitatively for 28 different features and analyzed using Multiple Factor Analysis (MFA) and optimal clustering was determined via maximization of Bayesian Information Criterion (BIC). Following bulk RNAseq, differential expression and pathway enrichment were performed using standard methodologies (i.e., DESeq2 and GSEA). RESULTS MRI features were well represented in the first 3 dimensions of MFA (variance explained=67.32%); specifically tumor/cyst size, ventricular size, and cyst fluid diffusivity. Using this three-way axis, we identified 3 patient subgroups. Transcriptional differences between these subgroups indicated one group was enriched for DNA damage response and MYC related pathways, one group enriched for SHH, and one group enriched for WNT/β-catenin and EMT-related pathways. CONCLUSION This preliminary work suggests that there may be unique gene expression variants within ACP, which may be identified preoperatively using easily quantifiable MRI parameters. These radiogenomic signatures could provide prognostic information and/or guidance in the selection of antitumor therapies for children with ACP.
Collapse
Affiliation(s)
| | - Eric Prince
- Children’s Hospital Colorado, Aurora, CO, USA
| | | | | | | | - James Johnston
- University of Alabama at Birmingham, Birmingham, AL, USA
| | - Luca Massimi
- Università Cattolica del Sacro Cuore, Rome, Italy
| | | | - Mark Souweidane
- Memorial Sloan Kettering Cancer Center, New York City, NY, USA
| | - Robert Naftel
- Vanderbilt University Medical Center, Nashville, TN, USA
| | - David Limbrick
- Washington University School of Medicine, St. Louis, MO, USA
| | - Gerald Grant
- Lucile Packard Children’s Hospital at Stanford University, Palo Alto, CA, USA
| | - Toba Niazi
- Nicklaus Children’s Hospital, Miami, FL, USA
| | | | | | - Eric Jackson
- Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - George Jallo
- Johns Hopkins All Children’s Hospital, St. Petersburg, FL, USA
| | - Kevin Ginn
- Children’s Mercy Hospital, Kansas City, MO, USA
| | - Amy Smith
- Arnold Palmer Hospital, Orlando, FL, USA
| | - Joshua Chern
- Emory University School of Medicine, Atlanta, GA, USA
| | - Amy Lee
- Seattle Children’s Hospital, Seattle, WA, USA
| | | | - Mark Krieger
- Children’s Hospital Los Angeles, Los Angeles, CA, USA
| | | | | |
Collapse
|
42
|
Roy J, Hunt J, Ecclestone H, Johnston J. Three's a crowd: A very rare form of polyorchidism with sertoli cell adenomas. Urol Case Rep 2020; 34:101512. [PMID: 33318937 PMCID: PMC7726671 DOI: 10.1016/j.eucr.2020.101512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2020] [Revised: 11/25/2020] [Accepted: 11/28/2020] [Indexed: 11/01/2022] Open
Abstract
Polyorchidism is rare with fewer than 200 cases reported in literature. We present a case of a 26 year old male with chronic pain secondary to a very rare form of polyorchidism, with histology showing Sertoli cell adenomas. Orchiectomy should be considered in patients with chronic pain due to polyorchidism.
Collapse
Affiliation(s)
- James Roy
- Taranaki Base Hospital, Taranaki District Health Board, 23 David Street, New Plymouth, New Zealand
| | - James Hunt
- Taranaki Pathology Services, 56 Vivan Street, New Plymouth, New Zealand
| | - Hazel Ecclestone
- Taranaki Base Hospital, Taranaki District Health Board, 23 David Street, New Plymouth, New Zealand
| | - James Johnston
- Taranaki Base Hospital, Taranaki District Health Board, 23 David Street, New Plymouth, New Zealand
| |
Collapse
|
43
|
Roy J, Johnston J, Ecclestone H. Female urethral stricture from chronic graft-versus-host disease. Urol Case Rep 2020; 34:101486. [PMID: 33224732 PMCID: PMC7666334 DOI: 10.1016/j.eucr.2020.101486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2020] [Revised: 11/02/2020] [Accepted: 11/05/2020] [Indexed: 10/26/2022] Open
Abstract
Female urethral strictures are rare with limited literature to guide management. We present a case of a 27 year old female diagnosed with a urethral stricture secondary to chronic graft-versus-host disease. This diagnosis should be considered in females presenting with obstructive voiding symptoms and have risk factors for stricture development.
Collapse
Affiliation(s)
- James Roy
- Taranaki Base Hospital, Taranaki District Health Board, 23 David Street, New Plymouth, New Zealand
| | - James Johnston
- Taranaki Base Hospital, Taranaki District Health Board, 23 David Street, New Plymouth, New Zealand
| | - Hazel Ecclestone
- Taranaki Base Hospital, Taranaki District Health Board, 23 David Street, New Plymouth, New Zealand
| |
Collapse
|
44
|
Clark ST, Johnston J, Biswas K, Douglas RG. Effect of tonsillectomy on antibiotic prescribing in children. Int J Pediatr Otorhinolaryngol 2020; 138:110338. [PMID: 33152956 DOI: 10.1016/j.ijporl.2020.110338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/27/2020] [Revised: 08/24/2020] [Accepted: 08/25/2020] [Indexed: 11/25/2022]
Abstract
INTRODUCTION Tonsillectomy is the second most common surgical procedure performed in pediatric otolaryngology. Multiple courses of antibiotics are usually prescribed prior to surgical intervention. Surgery is indicated when patients reach a certain number of infective episodes, or their obstructive symptoms warrant intervention. Little is known about the role of tonsillectomy on long term postoperative antibiotic use. Recently, our group published a retrospective case series that described the clinical characteristics and outcomes of children under the age of 16 years who underwent tonsillectomy. This study is a follow-up on this previous case series and its purpose is to determine whether tonsillectomy in this group of children led to a reduction in the number of antibiotics prescribed in the year following surgery. METHODS Data were collected from the clinical records departments of two district health boards in Auckland, New Zealand. Hospital morbidity records were reviewed for all children younger than 16 years old, who underwent a tonsillectomy between December 2015 and December 2017 in the Auckland region. All antibiotics prescribed following surgery were obtained from New Zealand's national community prescribing database. RESULTS A total of 1538 children underwent tonsillectomy during the study period. Following surgery, antibiotics were prescribed to 828 (54%) patients at the time of discharge, with an average of 1.2 ± 0.1 courses in the year following surgery. This was significantly reduced compared to preoperative antibiotic intake (3.4 ± 0.1 courses) in the year preceding surgery (p < 0.001). Readmission within 30 days of discharge was not associated with increased antibiotic usage postoperatively. In the two weeks following surgery, 25% of patients were prescribed a course of antibiotics for a presumed postoperative infection. CONCLUSIONS These findings support the benefit of tonsillectomy in reducing antibiotic consumption in the year following surgery. Furthermore, it has highlighted areas of practice, such as perioperative antibiotic prescription, which can be improved to further reduce the prescription of antibiotics for children with tonsillar hyperplasia.
Collapse
Affiliation(s)
- Sita Tarini Clark
- Department of Surgery, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
| | - James Johnston
- Department of Surgery, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.
| | - Kristi Biswas
- Department of Surgery, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
| | - Richard George Douglas
- Department of Surgery, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
| |
Collapse
|
45
|
Lux CA, Johnston J, Biswas K, Douglas RG. Efficacy of neutral electrolyzed water in postoperative chronic rhinosinusitis patients-a pilot study. Int Forum Allergy Rhinol 2020; 11:81-83. [PMID: 32881391 DOI: 10.1002/alr.22683] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2020] [Revised: 07/31/2020] [Accepted: 07/31/2020] [Indexed: 11/09/2022]
Affiliation(s)
- Christian Albert Lux
- School of Biological Sciences, University of Auckland, Auckland, New Zealand.,Department of Surgery, School of Medicine, University of Auckland, Auckland, New Zealand
| | - James Johnston
- Department of Surgery, School of Medicine, University of Auckland, Auckland, New Zealand
| | - Kristi Biswas
- Department of Surgery, School of Medicine, University of Auckland, Auckland, New Zealand
| | - Richard George Douglas
- Department of Surgery, School of Medicine, University of Auckland, Auckland, New Zealand
| |
Collapse
|
46
|
Johnston J, Vergeer A, Donaldson N, Shetty S, Mahadevan M. Our experience of the increased rates of post-tonsillectomy haemorrhage in 1538 children with pre-operative infective symptoms or signs. Clin Otolaryngol 2020; 45:944-945. [PMID: 32716583 DOI: 10.1111/coa.13610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2019] [Revised: 05/27/2020] [Accepted: 06/28/2020] [Indexed: 12/01/2022]
Affiliation(s)
- James Johnston
- Department of Surgery, University of Auckland, Auckland, New Zealand
| | - Aaron Vergeer
- Department of Surgery, University of Auckland, Auckland, New Zealand
| | - Natasha Donaldson
- Department of Surgery, University of Auckland, Auckland, New Zealand
| | | | - Murali Mahadevan
- Department of Surgery, University of Auckland, Auckland, New Zealand
| |
Collapse
|
47
|
Zimmerman K, May B, Barnes K, Arynchyna A, Alford EN, Arata C, Dreer L, Aban I, Johnston J, Rozzelle C, Blount JP, Rocque BG. Anxiety, depression, fatigue, and headache burden in the pediatric hydrocephalus population. J Neurosurg Pediatr 2020; 26:483-489. [PMID: 32707553 PMCID: PMC8934588 DOI: 10.3171/2020.4.peds19697] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/23/2019] [Accepted: 04/30/2020] [Indexed: 11/06/2022]
Abstract
OBJECTIVE Childhood hydrocephalus is a common chronic medical condition. However, little is known about the burden of headache and psychological comorbidities in children living with hydrocephalus. The purpose of this study was to determine the prevalence and severity of these conditions among the pediatric hydrocephalus population. METHODS During routine neurosurgery clinic visits from July 2017 to February 2018, the authors administered four surveys to children ages 7 years and older: Pediatric Migraine Disability Assessment (PedMIDAS), Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety, PROMIS Depression, and PROMIS Fatigue. The PedMIDAS is an assessment of headache disability in pediatric and adolescent patients. The PROMIS measures are pediatric self-reported instruments to assess social and emotional health. PROMIS measures utilize T-scores (mean 50, SD 10) to compare anxiety, depression, and fatigue in specific populations to those in the US general population. Clinical and demographic data were collected from the medical record (hydrocephalus etiology, shunt infection, race, etc.) and tested for associations with survey measure scores. RESULTS Forty children completed the PedMIDAS. Ten percent of them were in the severe headache range, 5% were in the moderate range, and 5% were in the mild range. There was a statistically significant association between undergoing a cluster of shunt operations and headache burden (p = 0.003).Forty children completed all three PROMIS measures. The mean anxiety score was 45.8 (SD 11.7), and 2.5% of children scored in the severe anxiety range, 17.5% in the moderate range, and 20% in the mild range. The mean depression score was 42.7 (SD 10.0), with 2.5% of children scoring in the severe depression range, 5% in the moderate range, and 12.5% in the mild range. The mean fatigue score was 45.1 (SD 16.4), with 15% percent of children scoring in the severe fatigue range, 10% in the moderate range, and 7.5% in the mild range. There were no statistically significant associations between child anxiety, depression, or fatigue and clinical or demographic variables. CONCLUSIONS Children with hydrocephalus have an average burden of headache, anxiety, depression, and fatigue as compared to the general population overall. Having a cluster of shunt operations correlates with a higher headache burden, but no clinical or demographic variable is associated with anxiety, depression, or fatigue.
Collapse
Affiliation(s)
- Kathrin Zimmerman
- Department of Neurosurgery, Division of Pediatrics, University of Alabama at Birmingham
| | - Bobby May
- School of Medicine, University of Mississippi Medical Center
| | - Katherine Barnes
- Department of Neurosurgery, Division of Pediatrics, University of Alabama at Birmingham
| | - Anastasia Arynchyna
- Department of Neurosurgery, Division of Pediatrics, University of Alabama at Birmingham
| | - Elizabeth N. Alford
- Department of Neurosurgery, Division of Pediatrics, University of Alabama at Birmingham
| | - Caroline Arata
- Department of Neurosurgery, Division of Pediatrics, University of Alabama at Birmingham
| | - Laura Dreer
- Department of Psychology, University of Alabama at Birmingham
| | - Inmaculada Aban
- Department of Statistics, University of Alabama at Birmingham
| | - James Johnston
- Department of Neurosurgery, Division of Pediatrics, University of Alabama at Birmingham
| | - Curtis Rozzelle
- Department of Neurosurgery, Division of Pediatrics, University of Alabama at Birmingham
| | - Jeffrey P. Blount
- Department of Neurosurgery, Division of Pediatrics, University of Alabama at Birmingham
| | - Brandon G. Rocque
- Department of Neurosurgery, Division of Pediatrics, University of Alabama at Birmingham
| |
Collapse
|
48
|
Le NNT, Liu TL, Johnston J, Krutty JD, Templeton KM, Harms V, Dias A, Le H, Gopalan P, Murphy WL. Customized hydrogel substrates for serum-free expansion of functional hMSCs. Biomater Sci 2020; 8:3819-3829. [PMID: 32543628 PMCID: PMC7436193 DOI: 10.1039/d0bm00540a] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
We describe a screening approach to identify customized substrates for serum-free human mesenchymal stromal cell (hMSC) culture. In particular, we combine a biomaterials screening approach with design of experiments (DOE) and multivariate analysis (MVA) to understand the effects of substrate stiffness, substrate adhesivity, and media composition on hMSC behavior in vitro. This approach enabled identification of poly(ethylene glycol)-based and integrin binding hydrogel substrate compositions that supported functional hMSC expansion in multiple serum-containing and serum-free media, as well as the expansion of MSCs from multiple, distinct sources. The identified substrates were compatible with standard thaw, seed, and harvest protocols. Finally, we used MVA on the screening data to reveal the importance of serum and substrate stiffness on hMSC expansion, highlighting the need for customized cell culture substrates in optimal hMSC biomanufacturing processes.
Collapse
Affiliation(s)
- Ngoc Nhi T Le
- Materials Science Program, University of Wisconsin-Madison, Madison, WI, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Landego I, Hewitt D, Hibbert I, Dhaliwal D, Pieterse W, Grenier D, Wong R, Johnston J, Banerji V. PD-1 inhibition in malignant melanoma and lack of clinical response in chronic lymphocytic leukemia in the same patients: a case series. ACTA ACUST UNITED AC 2020; 27:169-172. [PMID: 32669928 DOI: 10.3747/co.27.5371] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Chronic lymphocytic leukemia (cll) is the most common adult leukemia in the Western world. Unfortunately, affected patients are often immunosuppressed and at increased risk of infection and secondary malignancy. Previous meta-analysis has found that patients with cll have a risk of melanoma that is increased by a factor of 4 compared with the general population. Recent advances in the understanding of the PD receptor pathway have led to immunotherapies that target cancer cells. The use of PD-1 inhibitors is now considered first-line treatment for BRAF wild-type metastatic melanoma. Interestingly, early preclinical data suggest that inhibition of that pathway could also be used in the treatment of cll; however, recent clinical data did not support the effectiveness of that approach. In this case series, we highlight 2 cases in which patients with cll and concurrent malignant melanoma underwent treatment with PD-1 inhibitors and were found to experience reductions in their white blood cell counts without improvement in their hemoglobin. Those cases further illustrate that treatment of cll with PD-1 inhibitors is ineffective.
Collapse
Affiliation(s)
- I Landego
- Department of Internal Medicine, Rady College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB
| | - D Hewitt
- Research Institute of Oncology and Hematology, CancerCare Manitoba and the University of Manitoba, Winnipeg, MB
| | - I Hibbert
- Department of Nursing, CancerCare Manitoba, Winnipeg, MB
| | - D Dhaliwal
- Section of Hematology and Oncology, Rady College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB
| | - W Pieterse
- Russell Health Centre, Community Oncology Program, Winnipeg, MB
| | - D Grenier
- Section of Hematology and Oncology, Rady College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB
| | - R Wong
- Section of Hematology and Oncology, Rady College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB
| | - J Johnston
- Research Institute of Oncology and Hematology, CancerCare Manitoba and the University of Manitoba, Winnipeg, MB.,Section of Hematology and Oncology, Rady College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB
| | - V Banerji
- Research Institute of Oncology and Hematology, CancerCare Manitoba and the University of Manitoba, Winnipeg, MB.,Section of Hematology and Oncology, Rady College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB
| |
Collapse
|
50
|
Adams DQ, Alduino C, Alfonso K, Avignone FT, Azzolini O, Bari G, Bellini F, Benato G, Biassoni M, Branca A, Brofferio C, Bucci C, Caminata A, Campani A, Canonica L, Cao XG, Capelli S, Cappelli L, Cardani L, Carniti P, Casali N, Chiesa D, Chott N, Clemenza M, Copello S, Cosmelli C, Cremonesi O, Creswick RJ, D'Addabbo A, D'Aguanno D, Dafinei I, Davis CJ, Dell'Oro S, Di Domizio S, Dompè V, Fang DQ, Fantini G, Faverzani M, Ferri E, Ferroni F, Fiorini E, Franceschi MA, Freedman SJ, Fujikawa BK, Giachero A, Gironi L, Giuliani A, Gorla P, Gotti C, Gutierrez TD, Han K, Heeger KM, Huang RG, Huang HZ, Johnston J, Keppel G, Kolomensky YG, Ligi C, Ma YG, Ma L, Marini L, Maruyama RH, Mei Y, Moggi N, Morganti S, Napolitano T, Nastasi M, Nikkel J, Nones C, Norman EB, Novati V, Nucciotti A, Nutini I, O'Donnell T, Ouellet JL, Pagliarone CE, Pagnanini L, Pallavicini M, Pattavina L, Pavan M, Pessina G, Pettinacci V, Pira C, Pirro S, Pozzi S, Previtali E, Puiu A, Rosenfeld C, Rusconi C, Sakai M, Sangiorgio S, Schmidt B, Scielzo ND, Sharma V, Singh V, Sisti M, Speller D, Surukuchi PT, Taffarello L, Terranova F, Tomei C, Vignati M, Wagaarachchi SL, Wang BS, Welliver B, Wilson J, Wilson K, Winslow LA, Zanotti L, Zimmermann S, Zucchelli S. Improved Limit on Neutrinoless Double-Beta Decay in ^{130} Te with CUORE. Phys Rev Lett 2020; 124:122501. [PMID: 32281829 DOI: 10.1103/physrevlett.124.122501] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/23/2019] [Revised: 02/11/2020] [Accepted: 02/27/2020] [Indexed: 06/11/2023]
Abstract
We report new results from the search for neutrinoless double-beta decay in ^{130} Te with the CUORE detector. This search benefits from a fourfold increase in exposure, lower trigger thresholds, and analysis improvements relative to our previous results. We observe a background of (1.38±0.07)×10^{-2} counts/(keV kg yr)) in the 0νββ decay region of interest and, with a total exposure of 372.5 kg yr, we attain a median exclusion sensitivity of 1.7×10^{25} yr. We find no evidence for 0νββ decay and set a 90% credibility interval Bayesian lower limit of 3.2×10^{25} yr on the ^{130} Te half-life for this process. In the hypothesis that 0νββ decay is mediated by light Majorana neutrinos, this results in an upper limit on the effective Majorana mass of 75-350 meV, depending on the nuclear matrix elements used.
Collapse
Affiliation(s)
- D Q Adams
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - C Alduino
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - K Alfonso
- Department of Physics and Astronomy, University of California, Los Angeles, California 90095, USA
| | - F T Avignone
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - O Azzolini
- INFN-Laboratori Nazionali di Legnaro, Legnaro (Padova) I-35020, Italy
| | - G Bari
- INFN-Sezione di Bologna, Bologna I-40127, Italy
| | - F Bellini
- Dipartimento di Fisica, Sapienza Università di Roma, Roma I-00185, Italy
- INFN-Sezione di Roma, Roma I-00185, Italy
| | - G Benato
- Department of Physics, University of California, Berkeley, California 94720, USA
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
| | - M Biassoni
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
| | - A Branca
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - C Brofferio
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - C Bucci
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
| | - A Caminata
- INFN-Sezione di Genova, Genova I-16146, Italy
| | - A Campani
- INFN-Sezione di Genova, Genova I-16146, Italy
- Dipartimento di Fisica, Università di Genova, Genova I-16146, Italy
| | - L Canonica
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - X G Cao
- Key Laboratory of Nuclear Physics and Ion-Beam Application (MOE), Institute of Modern Physics, Fudan University, Shanghai 200433, China
| | - S Capelli
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - L Cappelli
- Department of Physics, University of California, Berkeley, California 94720, USA
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - L Cardani
- INFN-Sezione di Roma, Roma I-00185, Italy
| | - P Carniti
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - N Casali
- INFN-Sezione di Roma, Roma I-00185, Italy
| | - D Chiesa
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - N Chott
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - M Clemenza
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - S Copello
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
- Gran Sasso Science Institute, L'Aquila I-67100, Italy
| | - C Cosmelli
- Dipartimento di Fisica, Sapienza Università di Roma, Roma I-00185, Italy
- INFN-Sezione di Roma, Roma I-00185, Italy
| | - O Cremonesi
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
| | - R J Creswick
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - A D'Addabbo
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
| | - D D'Aguanno
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
- Dipartimento di Ingegneria Civile e Meccanica, Università degli Studi di Cassino e del Lazio Meridionale, Cassino I-03043, Italy
| | - I Dafinei
- INFN-Sezione di Roma, Roma I-00185, Italy
| | - C J Davis
- Wright Laboratory, Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - S Dell'Oro
- Center for Neutrino Physics, Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061, USA
| | - S Di Domizio
- INFN-Sezione di Genova, Genova I-16146, Italy
- Dipartimento di Fisica, Università di Genova, Genova I-16146, Italy
| | - V Dompè
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
- Gran Sasso Science Institute, L'Aquila I-67100, Italy
| | - D Q Fang
- Key Laboratory of Nuclear Physics and Ion-Beam Application (MOE), Institute of Modern Physics, Fudan University, Shanghai 200433, China
| | - G Fantini
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
- Gran Sasso Science Institute, L'Aquila I-67100, Italy
| | - M Faverzani
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - E Ferri
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - F Ferroni
- INFN-Sezione di Roma, Roma I-00185, Italy
- Gran Sasso Science Institute, L'Aquila I-67100, Italy
| | - E Fiorini
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - M A Franceschi
- INFN-Laboratori Nazionali di Frascati, Frascati (Roma) I-00044, Italy
| | - S J Freedman
- Department of Physics, University of California, Berkeley, California 94720, USA
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - B K Fujikawa
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - A Giachero
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - L Gironi
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - A Giuliani
- CSNSM, Univ. Paris-Sud, CNRS/IN2P3, Université Paris-Saclay, 91405 Orsay, France
| | - P Gorla
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
| | - C Gotti
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - T D Gutierrez
- Physics Department, California Polytechnic State University, San Luis Obispo, California 93407, USA
| | - K Han
- INPAC and School of Physics and Astronomy, Shanghai Jiao Tong University; Shanghai Laboratory for Particle Physics and Cosmology, Shanghai 200240, China
| | - K M Heeger
- Wright Laboratory, Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - R G Huang
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - H Z Huang
- Department of Physics and Astronomy, University of California, Los Angeles, California 90095, USA
| | - J Johnston
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - G Keppel
- INFN-Laboratori Nazionali di Legnaro, Legnaro (Padova) I-35020, Italy
| | - Yu G Kolomensky
- Department of Physics, University of California, Berkeley, California 94720, USA
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - C Ligi
- INFN-Laboratori Nazionali di Frascati, Frascati (Roma) I-00044, Italy
| | - Y G Ma
- Key Laboratory of Nuclear Physics and Ion-Beam Application (MOE), Institute of Modern Physics, Fudan University, Shanghai 200433, China
| | - L Ma
- Department of Physics and Astronomy, University of California, Los Angeles, California 90095, USA
| | - L Marini
- Department of Physics, University of California, Berkeley, California 94720, USA
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - R H Maruyama
- Wright Laboratory, Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - Y Mei
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - N Moggi
- INFN-Sezione di Bologna, Bologna I-40127, Italy
- Dipartimento di Fisica e Astronomia, Alma Mater Studiorum-Università di Bologna, Bologna I-40127, Italy
| | - S Morganti
- INFN-Sezione di Roma, Roma I-00185, Italy
| | - T Napolitano
- INFN-Laboratori Nazionali di Frascati, Frascati (Roma) I-00044, Italy
| | - M Nastasi
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - J Nikkel
- Wright Laboratory, Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - C Nones
- Service de Physique des Particules, CEA/Saclay, 91191 Gif-sur-Yvette, France
| | - E B Norman
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
- Department of Nuclear Engineering, University of California, Berkeley, California 94720, USA
| | - V Novati
- CSNSM, Univ. Paris-Sud, CNRS/IN2P3, Universit Paris-Saclay, 91405 Orsay, France
| | - A Nucciotti
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - I Nutini
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - T O'Donnell
- Center for Neutrino Physics, Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061, USA
| | - J L Ouellet
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - C E Pagliarone
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
- Dipartimento di Ingegneria Civile e Meccanica, Università degli Studi di Cassino e del Lazio Meridionale, Cassino I-03043, Italy
| | - L Pagnanini
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - M Pallavicini
- INFN-Sezione di Genova, Genova I-16146, Italy
- Dipartimento di Fisica, Università di Genova, Genova I-16146, Italy
| | - L Pattavina
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
| | - M Pavan
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - G Pessina
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
| | | | - C Pira
- INFN-Laboratori Nazionali di Legnaro, Legnaro (Padova) I-35020, Italy
| | - S Pirro
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
| | - S Pozzi
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - E Previtali
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - A Puiu
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - C Rosenfeld
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - C Rusconi
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
- INFN-Laboratori Nazionali del Gran Sasso, Assergi (L'Aquila) I-67100, Italy
| | - M Sakai
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - S Sangiorgio
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - B Schmidt
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - N D Scielzo
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - V Sharma
- Center for Neutrino Physics, Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061, USA
| | - V Singh
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - M Sisti
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - D Speller
- Wright Laboratory, Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | - P T Surukuchi
- Wright Laboratory, Department of Physics, Yale University, New Haven, Connecticut 06520, USA
| | | | - F Terranova
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - C Tomei
- INFN-Sezione di Roma, Roma I-00185, Italy
| | - M Vignati
- INFN-Sezione di Roma, Roma I-00185, Italy
| | - S L Wagaarachchi
- Department of Physics, University of California, Berkeley, California 94720, USA
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - B S Wang
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
- Department of Nuclear Engineering, University of California, Berkeley, California 94720, USA
| | - B Welliver
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - J Wilson
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - K Wilson
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - L A Winslow
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - L Zanotti
- INFN-Sezione di Milano Bicocca, Milano I-20126, Italy
- Dipartimento di Fisica, Università di Milano-Bicocca, Milano I-20126, Italy
| | - S Zimmermann
- Engineering Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - S Zucchelli
- INFN-Sezione di Bologna, Bologna I-40127, Italy
- Dipartimento di Fisica e Astronomia, Alma Mater Studiorum-Università di Bologna, Bologna I-40127, Italy
| |
Collapse
|